Abstract
During more than thirty years numerous compounds have been developed in the search for efficient antihypertensive drugs with qualitatively and quantitatively acceptable adverse reactions. The unwanted effects of hypotensive drugs constitute the main reason for the continuous development of new drugs and for changes in recommended therapy since many antihypertensives including the compounds dealt with here may generally be considered drugs of sufficient antihypertensive efficacy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abboud, F.M., Eckstein, J.W.: Effects of small oral doses of reserpine on vascular responses to tyramine and norepinephrine in man. Circulation 9, 219–223 (1964)
Abernathy, J.D.: The problem of non-compliance in long-term antihypertensive therapy. Drugs 11, Suppl. 1, 89–90 (1976)
Achor, R.W.P., Hanson, N.O., Gifford, R.W.: Hypertension treated with rauwolfia serpentine (whole root) and with reserpine. J. Am. Med. Assoc. 159, 841–845 (1955)
Adams, H.R., Smookler, H.H., Clarke, D.E., Jandhyala, B.S., Dixit, B.N., Ertel, R.J., Buckley, J.P.: Clinicopathologic effects of chronic reserpine administration in mongrel dogs. J. Pharm. Sci. 60, 1134–1138 (1971)
Adi, F.C., Eze, C.J., Anwunah, A.: Comparison of debrisoquine and guanethidine in treatment of hypertension. Br. Med. J. I, 482–485 (1975)
Adler, S.: Methyldopa-induced decrease in mental activity. J. Am. Med. Assoc. 230, 1428–1429 (1974)
Agnew, T.M., Irvine, R.O.H., North, J.D.K.: Methyldopa and hydrochlorothiazide compared with reserpine and hydrochlorothiazide. Br. Med. J. 2, 781–783 (1963)
Alexander, W.D., Evans, J.I.: Side effects of methyldopa. Br. Med. J. 2, 500 (1975)
Alkalay, L.: Thrombocytopenia due to methyldopa. Harefuah 89, 261–262 (1975)
Allum, W., Aminu, J., Bloomfield, T.H., Davies, C., Scales, A.H., Vere, D.W.: Interaction between debrisoquin and phenylephrine in man. Br. J. Clin. Pharmacol. 1, 51–57 (1974)
Alphin, R.S., Ward, J.W.: An investigation of antihistaminic activity and gastric ulceration. Eur. J. Pharmacol. 6, 61–66 (1969)
Ambrosino, S.V.: Depressive reactions associated with reserpine. N.Y. State J. Med. 74, 860–864 (1974)
Amery, A., Deloof, W.: Chesse reaction during debrisoquine treatment. Lancet 2, 613 (1970)
Aminu, J., D’Mello, A., Vere, D.W.: Interaction between debrisoquine and phenylephrine. Lancet 2, 935–936 (1970)
Anagnostakis, D., Matsaniotis, N.: Neonatal cold injury and maternal reserpine administration. Lancet 2, 471 (1974)
Angeletti, P.U., Levi-Montalcini, R.: Growth inhibition of sympathetic cells by some adrenergic blocking agents. Proc. Natl. Acad. Sci. USA 69, 86–88 (1972)
Angeletti, P.U., Levi-Montalcini, R., Caramia, F.: Structural and ultrastructural changes in developing sympathetic ganglia induced by guanethidine. Brain. Res. 43, 515–525 (1972)
Anselmino, K.J.: Die Behandlung der hypertensiven Spätgestose mit blutdrucksenkenden Mitteln unter besonderer Berücksichtigung der Eklampsie. Geburtshilfe Frauenheilkd. 20, 1097–1110 (1960)
Arglebe, C., West, J., Chilla, R.: Sialoadenosis produced by drug-treatment of hyper tonicity. II. Experimental studies on the effects of guanethidine (ismelin) on the submaxillary glands of the rat. Arch. Otorhinolaryngol. (NY) 211, 2590–265 (1975)
Armstrong, B., Stevens, N., Doll, R.: Retrospective study of the association between use of Rauwolfia derivatives and breast cancer in English women. Lancet 2, 672–675 (1974)
Armstrong, B., Skegg, D., White, G., Doll, R.: Rauwolfia derivative and breast cancer in hypertensive women. Lancet 2, 8–12 (1976)
Arnaud, G., Girod, C.: Nouvelles recherces concernant l’influence de la réserpine sur la gestation de la lapine. C.R. Soc. Biol. (Paris) 157, 1585–1586 (1963)
Aromaa, A., Hakama, M., Hakulinen, T., Saxén, E., Teppo, L., Idanpaan-Heikkila, J.: Breast cancer and use of rauwolfia and other antihypertensive agents in hypertensive patients: a nationwide case-control study in Finland. Int. J. Cancer 18, 727–738 (1976)
Athanassiadis, D., Cranston, W.I., Juel-Jensen, B.E., Oliver, D.O.: Clinical observations on the effects of debrisoquine sulphate in patients with high blood-pressure. Br. Med. J. 2, 732–735 (1966)
Ayd, F.D.: Drug-induced depression - fact or fallacy. N.Y. State J. Med. 58, 354–356 (1958)
Bachrach, W.H.: Reserpine, gastric secretion, and peptic ulcer. Am. J. Dig. Dis. 4, 117–124 (1959)
Bagwell, E.E., Woods, E.F., Durst, G.G.: Influence of reserpine on cardiovascular and sympathoadrenal responses to cyclopropane anesthesia in the dog. Anesthesiology 25, 148–155 (1964a)
Bagwell, E.E., Woods, E.F., Linker, R.P.: Influence of reserpine on cardiovascular and sympatho-adrenal responses to ether anesthesia in the dog. Anesthesiology 25, 15–24 (1964b)
Bak, I.J.: Electron microscopic observations in the substantia nigra of mouse during reserpine administration. Experientia 21, 568–570 (1965)
Bakemeier, R.F., Leddy, J.P.: Erythrocyte autoantibody associated with alpha-methyldopa: heterogeneity of structure and specificity. Blood 32, 1–14 (1968)
Balazs, T., Herman, E.H., Earl, F.L., Wolff, F.W.: Cardiotoxicity studies with diazoxide, reserpine, guanethidine and combinations of diazoxide and propranolol in dogs. Toxicol. Appl. Pharmacol. 33, 498–504 (1975)
Balmer, V.G.: Antihypertensive drugs and general anaesthesia. Med. J. Aust. 1, 143–148 (1965)
Barrett, W.E., Earl, A.E., Rogie, B.: Effect or reserpine on gastric secretion in the dog. J. Pharmacol. Exp. Ther. 113, 3 (1955)
Barron, K.D., Chang, T.Y., Daniels, A.C., Doolin, P.F.: Subcellular accompaniments of axon retraction in cervical motoneurones of the cat. In: Progress in neuropathology. Zimmerman, H.M. (ed.). New York-London: Grune & Stratton, Vol. 1, 255–280 (1971)
Bartolomé, J., Bartolomé, M., Seidler, F.J., Anderson, T.R., Slotkin, T.A.: Effects of early postnatal guanethidine administration on adrenal medulla and brain of developing rats. Biochem. Pharmacol. 25, 2387–2390 (1976a)
Bartolomé, J., Seidler, F.J., Anderson, T.R., Slotkin, T.A.: Effects of prenatal reserpine administration on development of the rat adrenal medulla and central nervous system. J. Pharmacol. Exp. Ther. 197, 293–302 (1976b)
Bartolomé, J., Slotkin, T.A.: Prenatal reserpine administration: Permanent changes in adrenal tyrosine hydroxylase and dopamine-β-hydroxylase. Psychopharmacol. Commun. 1, 465–472 (1975)
Bartolomé, J., Slotkin, T.A.: Effects of postnatal reserpine administration on sympathoadrenal development in the rat. Biochem. Pharmacol. 25, 1513–1519 (1976)
Bath, J., Pickering, D., Turner, R.: Clinical experience with bethanidine in treatment of hypertension. Br. Med. J. 4, 519–521 (1967)
Bauer, G.E., Croll, F.J.T., Goldrich, R.B., Jeremy, D., Raftos, J., Whyte, H.M., Young, A.A.: Guanethidine in treatment of hypertension. Br. Med. J. 2, 410–415 (1961)
Bauer, G.E., Hull, R.D., Stokes, G.S., Raftos, J.: The reversibility of side effects of guanethidine. Med. J. Aust. I, 930–933 (1973)
Bayliss, P.F.C., Duncan, S.M.: The effects of atenolol (tenormin) and methyldopa on simple tests of central nervous function. Br. J. Clin. Pharmacol. 2, 527–531 (1975)
Bayliss, R.I.S., Harvey-Smith, E.A.: Methyldopa in the treatment of hypertension. Lancet I, 763–768 (1962)
Becker-Christensen, F., Bang, H.O., Ditzel, J.: Treatment of severe hypertension with catapres (ST 155). A comparative study of the effect of catapres and methyldopa in a series of hypertensive outpatients (WHO stage III). Acta Med. Scand. 190, 21 - 26 (1971)
Bein, H.J.: The pharmacology of rauwolfia. Pharmacol. Rev. 8, 435–483 (1956)
Benraad, A.H., Schoenaker, A.H.: Thrombopenia after use of methyldopa. Lancet 2, 292 (1965)
Berger, W.: 88 schwere Hypoglykämiezwischenfalle unter der Behandlung mit Sulfunylharnstoffen. Schweiz. Med. Wochenschr. 101, 1013–1022 (1971)
Bernstein, S., Kaufman, M.R.: A psychological analysis of apparent depression following Rauwolfia therapy. J. Mt. Sinai Hosp. 27, 525–530 (1960)
Bhathal, P.S., Gerkens, J.F., Mashford, M.L.: Spermatic granuloma of the epididymis in rats treated with guanethidine. J. Pathol. 112, 19–26 (1974)
Bittiger, H., Maitre, L., Krinke, G., Schnider, K., Hess, R.: A study of long-term effects of guanethidine on peripheral noradrenergic neurones of the rat. Toxicology 8, 63–78 (1977)
Blahjchman, M.A., Pineo, G.G., Shimizu, A.G.: Methyldopa induced thrombocytopenia. Abstr. XIII Congr. Int. Soc. Blood Transf. p. 62 (1972)
Blaszkowski, T.P., Defeo, J.J., Guarino, A.M.: Central vs. peripheral catecholamines in rats during adaptation to chronic restraint stress. Pharmacology 4, 321–333 (1970)
Bloomfield, D.K., Cangiano, J.L.: Clinical experience with a new antihypertensive agent, guanadrel sulfate. Curr. Ther. Res. 11, 727–735 (1969)
Bloomfield, D.K., Cangiano, J.L.: Guanadrel and guanethidine in hypertension. Clin. Pharmacol. Ther. 11, 200–204 (1970)
Boardman, P.L., Robinson, K.C., Hart, F.D.: Guanoxan and systemic lupus erythematosus. Br. Med. J. 1, 111 (1967)
Bock, K.D., Heimsoth, V.: Persistierende orthostatische Hypotonie nach Behandlung mit Guanaclin. Dtsch. Med. Wochenschr. 94, 265–270 (1969)
Bock, K.D., Huep, W.W.: Irreversibler Parotisschmerz nach Verabreichung von Guanaclin. Dtsch. Med. Wochenschr. 96, 1649–1650 (1971)
Bonkowsky, H.L., Brisbane, J.: Colitis and hepatitis caused by methyldopa. J. Am. Med. Assoc. 236, 1602–1603 (1976)
Bosanec, P., Dubb, J., Walther, B., Goldberg, M., Agus, Z.S.: Renal effects of guanabenz: A new antihypertensive. J. Clin. Pharmacol. 16, 631–636 (1976)
Boston Collaborative Drug Surveillance Program: Reserpine and breast cancer. Lancet 2, 669–671 (1974)
Böttiger, L.E., Westerholm, B.: Drug-induced blood dyscrasias in Sweden. Br. Med. J. 3, 339–343 (1973)
Bouchier, I.A.D., Rhodes, K., Sherlock, S.: Serological abnormalities in patients with liver disease. Br. Med. J. 1, 592–596 (1964)
Bouillin, D.J.: A calcium requirement for release of 3H-guanethidine by sympathetic nerve stimulation. J. Pharm. Pharmacol. 18, 709–712 (1966)
Bouquet, J., Kroon, M.C., Rees, H. v., Stakenburg, J., Wolff, F.A. de, Noachi, E.L.: Influence of guanethidine on contractions of isolated seminal vesicles of the rat. Arch. Int. Pharmacodyn. Ther. 182, 402 (1969)
Boura, A.L.A., Green, A.F.: Comparison of bretylium and guanethidine: tolerance, and effects on adrenergic nerve function and responses to sympathomimetic amines. Br. J. Pharmacol. 19, 13–41 (1962)
Boura, A.L.A., Green, A.F.: Adrenergic neuron blocking agents. Ann. Rev. Pharmacol. Toxicol. 5, 183–212 (1965)
Boura, A.L.A., Copp, F.C., Green, A.F.: New antiadrenergic compounds. Nature (Lond.) 184, 70–71 (1959a)
Boura, A.A.L., Green, A.F., McCourbrey, A., Laurence, D.R., Moulton, R., Rosenheim, M.L.: Darenthin. Hypotensive agent of a new type. Lancet 2, 17–21 (1959b)
Bovet-Nitti, F., Bovet, D.: Action of some sympatholytic agents on pregnancy in the rat. Proc. Soc. Exp. Biol. Med. 100, 555–557 (1959)
Brater, D.C., Morrelli, H.F.: Cardiovascular drug interaction. Annu. Rev. Pharmacol. Toxicol. 1, 293–309 (1977)
Breckenridge, A., Dollery, C.T., Parry, E.H.O.: Prognosis of treated hypertension. Q. J. Med. 39, 411–429 (1970)
Brest, A.N.: Hemodynamic response to antihypertensive drug therapy. J. Am. Med. Assoc. 192, 41–44 (1965)
Brest, A.N., Moyer, J.H.: Therapeutic use of guanethidine. In Brest, A.N., Moyer, J.H. (eds.): Hypertension-recent advances. Philadelphia: Lea & Fibiger, 449–454 (1961)
Brest, A.N., Kodama, R., Naso, F., Moyer, J.H.: Guanethidine in the treatment of hypertension. Postgrad. Med. 30, 260–264 (1961a)
Brest, A.N., Seller, R., Onesti, G., Sekine, G., Moyer, J.H.: Preliminary observations on the antihypertensive effectiveness of alpha-methyl dopa, a decarboxylase inhibitor, In Brest, A.N., Moyer, J.H. (eds.): Hypertension - recent advances. Philadelphia, Lea & Fibiger, 424–429 (1961b)
Brest, A.N.,Novack, P., Kasparian, H., Moyer, J.H.: Guanethidine. Dis. Chest. 42, 359–363 (1962)
Brest, A.N., Onesti, G., Swartz, C., Seller, R., Kim, K.E., Chinitz, J.: Mechanisms of antihypertensive therapy. J. Am. Med. Assoc. 211, 480–484 (1970)
Brouillard, R.P., Barrett, O.: Methyldopa associated hepatitis. J. Am. Med. Assoc. 224, 904 (1973)
Brown, W.J., Brown, F.K.: The use of guanethidine and hydrochlorothiazide in the long-term treatment of essential hypertension. Curr. Ther. Res. 17, 544–554 (1975)
Brown, J.H., Nelson, D.L., Molinoff, A.: Organ culture of rat superior cervical ganglia. J. Pharmacol. Exp. Ther. 201, 293–311 (1977)
Bruhn-Petersen, F.: Methyldopum-drug fever. Ugeskr. Laeger 129, 639–641 (1967)
Bryant, J.M., Schwartz, N., Fertig, H., Fletcher, L., Quan, R.B.F.: Prolonged antihypertensive drug potentiation following isocaramidine withdrawal: A new therapeutic effect. J. New Drugs 4, 221 (1964)
Budnick, I.S., Leikin, S., Hoeck, L.E.: Effect in the newborn infant of reserpine administration ante partum. Am. J. Dis. Child. 90, 286–289 (1955)
Bulpitt, C.J., Dollery, C.T.: Side effects of hypotensive agents evaluated by a self-administered questionnaire. Br. Med. J. 3, 485–490 (1973)
Burden, A.C., Alexander, C.P.T.: Rebound hypertension after acute methyldopa withdrawal. Br. Med. J. 1, 1056–1057 (1976)
Burns-Cox, C.J.: Negative Coombs test in Chinese on methyldopa. Lancet 2, 673–674 (1970)
Burnstock, G., Doyle, A.E., Gannon, B.J., Gerkens, J.F., Iwayama, T., Mashford, M.L.: Prolonged hypotension and ultrastructural changes in sympathetic neurons following guanacline treatment. Eur. J. Pharmacol. 13, 175–187 (1971a)
Burnstock, G., Evans, B., Gannon, B.J., Heath, J.W., James, V.: A new method of destroying adrenergic nerves in adult animals using guanethidine. Br. J. Pharmacol. 43, 295–301 (1971b)
Burnstock, G., Gannon, B., Iwayama, T.: Sympathetic innervation of vascular smooth muscle in normal and hypertensive animals. Circ. Res. 26–27, Suppl. 2, 5–21 (1970)
Burry, J.N.: Ulcerative lichenoid eruption from methyldopa. Arch. Dermatol. 112, 880 (1976)
Burry, J.N., Kirk, J.: Lichenoid drug reaction from methyldopa. Br. J. Dermatol. 91, 475–476 (1974)
Byrd, G.J.: Methyldopa and lithium carbonate: Suspected interaction. J. Am. Med. Assoc. 233, 320 (1975)
Cacace, L.G., Cohen, M.: Alpha-methyldopa (Aldomet) hepatitis. Drug. Intell. Clin. Pharmacol. 10, 144–152 (1976)
Cairoli, V.J., Reilly, J.F., Roberts, J.: Effect of reserpine pretreatment on the response of isolated papillary muscle to ephedrine. Br. J. Pharmacol. 18, 588–594 (1962)
Cannon, P.J., Laragh, J.H.: Treatment of hypertension with alpha-methyl-dopa. Pharmakotherapia 1, 171–184 (1963)
Cantor, S., Barnett, A.J.: Haematological effects of methyldopa. Lancet 1, 625 (1967)
Caramia, F., Angeletti, P.U., Levi-Montalcini, R., Carratelli, L.: Mitochondrial lesions of developing sympathetic neurons induced by bretylium tosylate. Brain Res. 40, 237–246 (1972)
Carminati, G.M.: Attività comparata di svariati farmaci in alcuni tests sperimentali di syudio del comportamento. Arch. Int. Pharmacodyn. Ther. 181, 68–93 (1969)
Carstairs, K.C., Breckenridge, A., Dollery, C.T., Worlledge, S.M.: Incidence of a positive direct Coombs test in patients on α-methyldopa. Lancet 2, 133–135 (1966a)
Carstairs, K.C., Worlledge, S., Dollery, C.T., Breckenridge, A.: Methyldopa and haemolytic anaemia. Lancet 1, 201 (1966b)
Chamberlain, D.A., Howard, J.: Guanethidine and methyldopa: A haemodynamic study. Br. Heart. J. 26, 528–536 (1964)
Chan, C.S., Chan, T.K., Lee, S.K.: Direct Coombs test and methyldopa. Lancet 2, 881 (1971)
Chaplin, H., Avioli, L.V.: Autoimmune hemolytic anemia. Arch. Intern. Med. 137, 346–351 (1977)
Chessin, M., Kramer, E.R., Scott, C.C.: Modifications of the pharmacology of reserpine and serotonin by iproniazid. J. Pharmacol. Exp. Ther. 119, 453–460 (1957)
Chidell, M.P., Whiteside, J.D.: A hypertension clinic. Four years’ experience in a provincial hospital. Practitioner 202, 542–552 (1969)
Chilla, R., Rieger, R., Arglebe, C.: Sialoadenosis produced by drug-treatment of hypertonicity. I. Experimental studies on the effects of guanethidine (ismelin) on the parotid gland of the rat. Arch. Otorhinolaryngol. (NY) 211, 185–192 (1975)
Christopher, L.J., Crooks, J., Davidson, J.F., Erskine, Z.G., Gallon, S.C., Moir, D.C., Weir, R.D.: A multicentre study of rauwolfia derivatives and breast cancer. Eur. J. Clin. Pharmacol. 11, 409–417 (1977)
Chrysant, S.G., Frohlich, E.D.: Comparison of the antihypertensive effectiveness of guanadrel and guanethidine. Curr Ther. Res. 19, 379–385 (1976)
Church, R.: Methyldopa causing seborrhoic dermatitis-like eruption. Br. J. Dermatol. 89, Suppl. 9, 10 (1973)
Church, R.: Eczema provoked by methyl dopa. Br. J. Dermatol. 91, 373–378 (1974)
Ciba Pharmaceutical Company Information. In Barnes, C.D., Eltherington, L.G.: Drug dosage in laboratory animals. Berkeley-Los Angeles-London: University of California Press, (1973), p. 112 and 234
Clarke, D.E., Jandhyala, B.S., Caverò, I., Dixit, B.N., Buckley, J.P.: A differential effect of chronically administered guanethidine on sympathetic neurotransmission to the dog heart and mesenteric arterial blood vessels. Can. J. Physiol. Pharmacol. 52, 641–648 (1974)
Clementi, F.: Modifications ultrastructurelles provoquées par quelques médicaments sur les terminaisons nerveuses adrénergiques et sur la médullaire surrénale. Experientia (Basel) 21, 171–176 (1965)
Coffman, J.D.: Persistence of reflex sympathetic nervous system activity in man on guanethidine or reserpine. Circulation 35, 339–346 (1967)
Cohen, S.I., Young, M.W., Lau, S.H., Haft, J.I., Damato, A.N.: Effects of reserpine therapy on cardiac output and atrioventricula conduction during rest and controlled heart rates in patients with essential hypertension. Circulation 37, 738–746 (1968)
Cohn, J.N., Liptake, T.E., Freis, E.D.: Hemodynamic effects of guanethidine in man. Circ. Res. 12, 298–307 (1963)
Cole, M.: Retrograde degeneration of axon and soma in the nervous system. In: Bourne, G.H. (ed.): The structure and function of nervous tissue. New York-London: Academic Press, (1968), pp. 269–300
Colwill, J.M., Dutton, A.M., Morrissey, J. Yu, P.N.: Alpha-methyldopa and hydrochlorothiazide. A controlled study of their comparative effectiveness as antihypertensive agents. N. Engl. J. Med. 271, 696–703 (1964)
Conston, A.S.: Hypersensitivity myocarditis: A fatal reaction. J. Med. Soc. N. J. 71, 61 (1974)
Costa, E., Kuntzman, R., Gessa, H.L., Brodie, B.B.: Structural requirements for bretylium and guanethidine-like activity in a series of guanidine derivatives. Life Sci. 3, 75–80 (1962)
Cotton, S.G., Montuschi, E.: Side-effects of guanoxan. Br. Med. J. 1, 51 (1966)
Cotton, S.G., Montuschi, E.: Guanoxan. Br. Med. J. 3, 174 (1967)
Coulter, J.D., Lester, B.K., Williams, H.L.: Reserpine and sleep. Psychopharmacology 19, 134–147 (1971)
Cragg, B.G.: What is the signal for chromatolysis? Brain Res. 23, 1–21 (1970)
Cranston, W.I., Brown, W.: Diurnal variation in plasma volume in normal and hypertensive subjects. Clin. Sci. Mol. Med. 25, 107–114 (1963)
Cunningham, J.A.K.: Hypertension and cardiovascular disease, adverse effects of guanethidine. N. Z. Med. J. 66, 373–378 (1967)
Curwain, B.P., Fake, C.S., Gordon, J.L., Mehta, M.D., Miller, D., Poyser, R.H., Wates, E.A.: Synthesis and antihypertensive properties of some N-(guanidinoalkyl)pyrrolidines. J. Med. Chem. 14, 737–742 (1971)
Dameshek, W.: Alpha-methyldopa red cell antibody: cross reaction or forbidden clones. N. Engl. J. Med. 276, 1382 (1967)
Dandiya, P.C., Menon, M.K., Studies on central nervous system depressants. (Ill) Influence of some tranquilizing agents on morphine analgesia. Arch. Int. Pharmacodyn. Ther. 141, 223–232 (1963)
Davey, M.J., Reinert, H.: Pharmacology of the antihypertensive guanoxan. Br. J. Pharmacol. 24, 29–48 (1965)
Dawborn, J.K., Doyle, A.E., Ebringer, A., Howqua, J., Jerums, C., Johnston, C.I., Mashford, M.L., Parkin, J.D.: Persistent postural hypotension due to guanacline. Pharmacol. Clin. 2, 1–5 (1969)
Day, M.D.: Effect of sympathomimetic amines on the blocking action of guanethidine, bretylium, and xylocholine. Br. J. Pharmacol. 18, 421–439 (1962)
Day, M.D., Rand, M.J.: Antagonism of guanethidine ande bretylium by various agents. Lancet 2, 1282–1283 (1962)
Day, M.D., Rand, M.J.: Evidence for a competitive antagonism of guanethidine by dexamphetamine. Br. J. Pharmacol. 20, 17–28 (1963)
Denney, J.L., Frasher, W.G., Hoytt, D.D.: Clinical evaluation of drug therapy in hypertension. Am. J. Med. Sci. 230, 269–281 (1955)
Desmond, M.M., Rogers, S.F., Lindley, J.E., Moyer, J.H.: Management of toxemia of pregnancy with reserpine. II. The newborn infant. Obstet. Gynecol. 10, 140–145 (1957)
Dewaard, F., Halewijn, E.A.B, van: A prospective study in general practice of breast-cancer risk in postmenopausal women. Int. J. Cancer 14, 153–160 (1974)
Dewar, H.A., Peaston, M.J.T.: Three cases resembling polyarteritis nodosa arising during treatment with guanethidine. Br. Med. J. 2, 609–611 (1964)
Dick, H.L.H., McCawley, E.L., Fischer, W.A.: Reserpine-digitalis toxicity. Arch. Intern. Med. 109, 503–506 (1962)
Djaldetti, M., Bessler, H., Lewinski, U., Mandel, E.M.: Inhibition of uridine incorporation in proerythroblasts of patients with α-methyldopa induced haemolytic anaemia. Br. J. Haematol. 27, 579–586 (1974)
Dollery, C.T.: Methyldopa in the treatment of hypertension. Prog. Cardiovasc. Dis. 8, 278–289 (1965a)
Dollery, C.T.: Physiological and pharmacological interactions of antihypertensive drugs. Proc. R. Soc. Med. 58, 983–987 (1965b)
Dollery, C.T.: Pharmacological basis for combination therapy of hypertension. Annu. Rev. Pharmacol. Toxicol. 17, 311–323 (1977)
Dollery, C.T., Harington, M.: Methyldopa in hypertension, Clinical and pharmacological studies. Lancet 1, 759–763 (1962)
Dollery, C.T., Emslie-Smith, D., McMichael, J.: Bretylium tosylate in the treatment of hypertension. Lancet 2, 261–262 (1960a)
Dollery, C.T., Emslie-Smith, D., Milne, M.D.: Clinical and pharmacological studies with guanethidine in the treatment of hypertension. Lancet 2, 381–387 (1960b)
Dollery, C.T., Harington, M., Hodge, J.V.: Haemodynamic studies with methyldopa: Effects on cardiac output and responses to pressor amines. Br. Heart J. 25, 670–676 (1963)
Donath, K.: Ultrastrukturelle Acinusveränderungen der Rattenparotis unter der Einwirkung von Antihypertensiva (Guanacline). Arch. Otorhinolaryngol. (NY) 206, 77–90 (1973)
Donath, K., Seifert, G.: Veränderungen des vegetativen Nervensystems der Parotis nach Einwirkung von Antihypertensiva (Guanacline). Virchows Arch. [Pathol. Anat.] 361, 109–120 (1973)
Donath, K., Seifert, G., Pirsig, W.: Parotis-Sialadenosis nach Langzeittherapie mit Antihypertensiva (Guanacline). Virchows Arch. [Pathol. Anat.] 360, 33–44 (1973)
Dörner, G., Hecht, K., Hinz, G.: Teratopsychogenetic effects apparently produced by non- physiological neurotransmitter concentrations during brain differentiation. Endokrinologie 68, 1–5 (1976)
Douglas, R.M.: Hypertensive cerebrovascular damage: considered in relation to treatment with hypotensive drugs. Med. J. Aust. 2, 525–533 (1964)
Downing, O.A., Juul, P.: The effect of guanethidine pretreatment on transmission in the superior cervical ganglion. Acta Pharmacol. Toxicol. (Kbh) 32, 369–381 (1973)
Draškoci, M., Jankoviö, B.D.: Involution of thymus and suppression of immune responses in rats treated with guanethidine. Nature 202, 408–409 (1964)
Drew, J.H., Kitchen, W.H.: The effect of maternally administered drugs on bilirubin concentrations in the newborn infant. J. Pediatr. 89, 657–661 (1976)
Dunn, M.I., Freeman, J.: Moderate hypertension: Treatment with guanethidine and methyldopa. Curr. Ther. Res. 18, 285–291 (1975)
Dustan, H.P., Tarazi, R.C., Bravo, E.L.: Dependence of arterial pressure on intravascular volume in treated hypertensive patients. N. Engl. J. Med. 286, 861–866 (1972)
Duvoisin, R.C., Marsden, C.D.: Reversal of reserpine-induced bradykinesia by α-methyldopa-new light on its modus operandi. Brain Res. 71, 178–182 (1974)
Dybing, E., Nelson, S.D., Mitchell, J.R., Sasame, H.A., Gillette, J.R.: Oxidation of α-methyldopa and other catechols by cytochrome P-450-generated superoxide in man: Possible mechanism of methyldopa hepatitis. Mol. Pharmacol. 12, 911–920 (1976)
Dyer, A.R., Stamler, J., Berkson, D.M., Lindberg, H.A., Stevens, E.: High blood-pressure: A risk factor for cancer mortality, Lancet 1, 1051–1056 (1975)
Eger, E.I., Hamilton, W.K.: The effect of reserpine on the action of various vasopressors. Anesthesiology 20, 641–645 (1959)
Eliastam, M.: Hepatitis, arthritis and lupus cell phenomena caused by methyldopa. Digest. Dis. 16, 1014–1018 (1971)
Elkington, S.G., Schreiber, W.M., Conn, H.O.: Hepatic injury caused by L-alpha-methyldopa. Circulation 40, 589–595 (1969)
Eränkö, O., Eränkö, L.: Histochemical evidence of chemical sympathectomy by guanethidine in newborn rats. Histochem. J. 3, 451–456 (1971a)
Eränkö, L., Eränkö, O.: Effect of guanethidine on nerve cells and small intensely fluorescent cells in sympathetic ganglia of newborn and adult rats. Acta Pharmacol. Toxicol. (Kbh) 30, 403–410 (1971b)
Eränkö, L., Hill, c., Eränkö, O., Burnstock, G.: Lack of toxic effect of guanethidine on nerve cells in cultures of sympathetic ganglia of newborn rats. Brain Res. 43, 501–513 (1972)
Euler, U.S. v.: Synthesis, uptake, and storage of catecholamines in adrenergic nerves, the effect of drugs. In: Blaschko, H. and Muscholl, E. (eds.): Catecholamines. Handbook of ex-perimental pharmacology, vol. 33. Berlin-Heidelberg-New York, Springer Verlag, 186–230 (1972)
Evans, B., Gannon, B.J., Heath, J.W., Burnstock, G.: Long-lasting damage to the internal male genital organs and their adrenergic innervation in rats following chronic treatment with the antihypertensive drug guanethidine. Fertil. Steril. 23, 657–667 (1972)
Eyster, M.E., Jenkins, D.E.: Gamma G erythrocyte auto-antibodies: Comparison of in vivo complement coating and in vitro “Rh” specificity. J. Immunol. 105, 221-226 (1970)
Fann, W.E., Janowsky, D.S., Davis, J.M., Oates, J.A.: Chlorpromazine reversal of the antihypertensive action of guanethidine. Lancet 2, 436–437 (1971)
Fann, W.E., Cavanaugh, J.H., Kaufmann, J.S., Griffith, J.D., Davis, J.M., Janowsky, D.S., Oates, J.A.: Doxepin: effects on transport of biogenic amines in man. Psychopharmacologia 22, 111–125 (1972)
Ferguson, R.K., Rothenburg, R.J., Nies, A.S.: Patient acceptance of guanethidine as therapy for mild to moderate hypertension. A comparison with reserpine. Circulation 54, 32–37 (1976)
Fernandez, P.G.: Alpha methyldopa and forgetfulness. Ann. Intern. Med. 85, 128 (1976)
Finch, L.: Vascular reactivity in hypertensive rats after treatment with anti-hypertensive agents. Life Sci. 15, 1827–1836 (1974)
Finnerty, F.A., Davidov, M., Mroczek, W.J., Gavrilovich, L.: Influence of extracellular fluid volume on response to antihypertensive drugs. Circ. Res. 27, Suppl. 1, 71–80 (1970)
Fischer, J.E., Weise, V.K., Kopin, I.J.: Release of tritiated bretylium by sympathetic nerve stimulation. Nature (Lond.) 209, 778–779 (1966)
Fleming, W.W.: Supersensitivity of the cat heart to catecholamine-induced arrhythmias following reserpine. Proc. Soc. Exp. Biol. Med. 111, 484–486 (1962)
Fleming, W.W., Trendelenburg, U.: Development of supersensitivity to norepinephrine after pretreatment with reserpine. J. Pharmacol. Exp. Ther. 133, 41–51 (1961)
Forrester, T.M., Sheriffs, G.G.: Methyldopa and methoserpidine in hypertension. A double-blind trial. Lancet 1, 141–142 (1967)
Freis, E.D.: Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N. Engl. J. Med. 251, 1006–1008 (1954)
Friedberg, V.: Über die perinatale Sterblichkeit bei Neugeborenen bei Präeklampsien. Geburtshilfe Frauenheilkd. 24, 649–660 (1964)
Frohlich, E.D.: Inhibition of adrenergic function in the treatment of hypertension. Arch. Intern. Med. 133, 1033–1048 (1974)
Frohlich, E.D., Freis, E.D.: Clinical trial of guanethidine, a new type of antihypertensive agent. Medical Annals, District of Columbia 28, 419–422 (1959)
Fullerton, A.G., Morton-Jenkins, D.: Methyldopa and depression. Br. Med. J. 1, 538–539 (1975)
Furst, C.I.: The biochemistry of guanethidine. Adv. Drug Res. 4, 133–161 (1967)
Galskov, Á., Clausen, E., Hilden, T., Krogsgaard, A.R.: Guanethidine in the ambulatory treatment of arterial hypertension. Acta Med. Scand. 170, 31–42 (1961)
Gannon, B.J., Iwayama, T., Burnstock, G., Gerkens, J., Mashford, M.L.: Prolonged effects of chronic guanethidine treatment on the sympathetic innervation of the genitalia of male rats. Med. J. Aust. 2, 207–208 (1971)
Garfinkel, L., Hammond, E.C.: Breast cancer and hypertension. Lancet 2, 1381 (1974)
Gaunt, R., Renzi, A.A., Antonchak, N., Miller, G.J.: Endocrine aspects of the pharmacology of reserpine. Ann. N. Y. Acad. Sci. 59, 22–35 (1959)
Gelfand, M.L., Goodkin, L.: Drug-induced gastrointestinal bleeding. N. Y. J. Med. 58, 2381–2384 (1958)
Gerkens, J.F.: Guanethidine and guanacline on the rat vas deferens. Br. J. Pharmacol. 52, 191–195 (1974a)
Gerkens, J.F.: Effect of long-term treatment with guanacline or guanethidine on sympathetic function. Eur. J. Pharmacol. 26, 143–150 (1974b)
Ghosh, S.K.: Methyldopa and forgetfulness. Lancet 1, 202–203 (1976)
Giachetti, A., Hollenbeck, R.A.: Extra-vesicular binding of noradrenaline and guanethidine in the adrenergic neurones of the rat heart: A proposed site of action of adrenergic neurone blocking agents. Br. J. Pharmacol. 58, 497–504 (1976)
Gibb, W.E., Malpas, J.S., Turner, P., White, R.J.: Comparison of bethanidine, α-methyldopa, and reserpine in essential hypertension. Lancet 2, 275–277 (1970)
Gifford, R.W.: Management of hypertensive emergencies. Postgrad. Med. 34, 145–149 (1963)
Gifford, R.W.: Bethanidine sulfate - a new antihypertensive agent. J. Am. Med. Assoc. 193, 901–905 (1965)
Gilder, J.E.V.: Alpha-methyldopa-induced immune hemolytic anemia. W. Va. Med. J. 71, 327–332 (1975)
Gill, J.R., Bartter, F.C.: Adrenergic nervous system in sodium metabolism. N. Engl. J. Med. 275, 1466–1471 (1966)
Gill, J.R., Mason, D.T., Bartter, F.C.: Adrenergic nervous system in sodium metabolism: Effects of guanethidine and sodium-retaining steroids in man. J. Clin. Invest. 43, 177–184 (1976)
Gillespie, L., Oates, J.A., Crout, J.H., Sjoerdsma, A.: Clinical and chemical studies with α-methyl-dopa in patients with hypertension. Circulation 25, 281–291 (1962)
Gillies, J.D.: A complication of alpha-methyldopa therapy. Anaesth. Intensive Care 2, 179–181 (1974)
Gilmore, B.L., Freis, E.D.: Methyldopa in the treatment of hypertension. Med. Ann. D. C. 34, 13–18 (1965)
Glazer, N.: Reserpine, hydralazine, hydrochlorothiazide combination (ser-ap-es) in essential hypertension. Curr. Ther. Res. 14, 561–572 (1972)
Glazer, N.: Comparison of guanethidine and methyldopa in essential hypertension: A controlled study. Curr. Ther. Res. 17, 249–256 (1975)
Glontz, G.E., Saslaw, S.: Methyldopa fever. Arch. Intern. Med. 122, 445–447 (1968)
Gokhale, S.D., Gulati, O.D.; Udwadia, B.P.: Antagonism of the adrenergic neuron blocking action of guanethidine by certain antidepressants and antihistaminic drugs. Arch. Int. Pharmacodyn. Ther. 160, 321–329 (1966)
Gokhale, S.D., Gulati, O.D., Kelkar, V.V.: Supersensitivity to catecholamines following gua¬nethidine. Br. J. Pharmacol. 30, 445–462 (1967)
Goldberg, A.D., Raftery, E.B.: Patterns of blood-pressure during chronic administration of postganglionic sympathetic blocking drugs for hypertension. Lancet 2, 1052–1054 (1976)
Goldman, A.S., Yakovac, W.C.: Teratogenic action in rats of reserpine alone and in combination with salicylate and immobilization. Proc. Soc. Exp. Biol. Med. 118, 857–862 (1965)
Goldstein, G.B., Lam, K.C., Mistilis, S.P.: Drug-induced active chronic heptatitis. Am. J. Dig. Dis. 18, 177–184 (1973)
Gormsen, J., Dyrbye, M., Eiken, M., Ronnov-Jessen, V.: Acute cerebral infarct. Extracerebral genesis with particular reference to cardiovascular status. Acta Med. Scand. 169, 455–466 (1961)
Gradwell, B.G.: Psychotic reactions and phenelzine. Br. Med. J. 2, 1018 (1960)
Green, A.F., Robson, R.D.: Adrenergic neurone blocking agents: Tolerance and hypersensitivity to adrenaline and noradrenaline. Br. J. Pharmacol. 25, 497–506 (1965)
Greene, R. Spence, A.W.: Neutropenia caused by methyldopa. Br. Med. J. 4, 618 (1967)
Grenfell, R.F.: Treatment of hypertensive crisis. Chest 59, 212–213 (1971)
Groden, B.M.: Parkinsonism occurring with methyldopa treatment. Br. Med. J. 1, 1001 (1963)
Groover, M.E., Fulghum, J.E., Simpson, W.G.: Arterial hypertension - Northwest Florida Health Survey. II. Diagnosis and treatment. Curr. Ther. Res. 16, 1203–1213 (1974)
Gross, F. (ed.): Antihypertensive agents. Handbook of experimental pharmacology, Vol. 39. Berlin-Heidelberg-New York: Springer Verlag (1977)
Guazzi, M., Magrini, F., Fiorentini, C., Polese, A.: Role of the sympathetic nervous system in supporting cardiac function in essential arterial hypertension. Br. Heart J. 35, 55–64 (1973a)
Guazzi, M., Polese, A., Fiorentini, C., Magrini, F.: Importance of the adrenergic nervous system in the support of cardiac function in patients with arterial hypertension. Clin. Sci. Mol. Med. 45, Suppl. 1, 1515–1545 (1973b)
Gulati, O.D., Dave, S.D., Gokhale, S.D., Shah, K.M.: Antagonism of adrenergic neuron blockade in hypertensive subjects. Clin. Pharmacol. Ther. 7, 510–514 (1966)
Gupta, K.K.: The anti-diabetic action of guanethidine. Postgrad. Med. J. 45, 455–456 (1969)
Gupta, K.K., Lillicrap, C.A.: Guanethidine and diabetes. Br. Med. J. 2, 697–698 (1968)
Gupta, M.B., Tangri, K.K., Bhargava, K.P.: Mechanism of ulcerogenic action of reserpine in albino rats. Eur. J. Pharmacol. 27, 269–271 (1974)
Haeusler, G., Haefely, W., Huerliman, A.: On the mechanism of the adrenergic blocking action of bretylium and guanethidine. Arch. exp. Path. Pharmak. 264, 241–243 (1969)
Haeusler, G., Lorez, H.P., Bartholini, G., Kettler, R., Tranzer, J.P.: Absence of degeneration of adrenergic neurons after prolonged treatment with debrisoquin. J. Pharmacol. Exp. Ther. 189, 646–658 (1974)
Hallwright, G.P.: Agranulocytosis caused by methyl dopa (Aldomet). N. Z. Med. J. 60, 567–570 (1961)
Hamilton, M.: Some aspects of the long-term treatment of severe hypertension with methyldopa. Postgrad. Med. J. 44, 66–69 (1968)
Hamilton, M., Kopelman, H.: Treatment of severe hypertension with methyldopa. Br. Med. J. 1, 151–155 (1963)
Hanahoe, T.H.P., Ireson, J.D., Large, B.J.: Interactions between guanethidine and inhibitors of noradrenaline uptake. Arch. Int. Pharmacodyn. Ther. 182, 349–353 (1969)
Hans, S.F., Kopelman, H.: Methyldopa in treatment of severe toxaemia of pregnancy. Br. Med. J. 1, 736–739 (1964)
Hansen, J.: Alpha-methyl-dopa (Aldomet) in the treatment of hypertension. Acta Med. Scand. 183, 323–327 (1968)
Hansson, L., Pascual, A., Julius, S.: Comparison of guanadrel and guanethidine. Clin. Pharmacol. Ther. 14, 204–208 (1973)
Harrison, D.C., Chidsey, C.A., Goldman, R., Braunwald, E.: Relationships between the release and tissue depletion of norepinephrine from the heart by guanethidine and reserpine. Circ. Res. 12, 256–263 (1963)
Hartmann, E.: Reserpine: Its effect on the sleep-dream cycle in man. Psychopharmacologia 9, 242–247 (1966)
Harvald, B., Schaumburg, E.: Debrisokin som led i kombineret antihypertensiv terapi. Ugeskr. Laeger 138, 420–422 (1976)
Haverback, B.J., Stevenson, T.D., Sjoerdsma, A., Terry, L.L.: The effect of reserpine and chlorpromazine on gastric secretion. Am. J. Med. Sci. 230, 601–604 (1955)
Heath, J.W., Sobels, G.: Intracellular site of action of guanethidine on adrenergic neurons. In: Drug design and adverse reactions. Bundgaard, H., Juul, P., Kofod, H. (eds.): Copenhagen: Munksgaard, (1977), pp. 52 - 60
Heath, J.W., Evans, B.K., Gannon, B.J., Burnstock, G., James, V.B.: Degeneration of adrenergic neurons following guanethidine treatment: An ultrastructural study. Virchows Arch. [Cell Pathol.] 11, 182–197 (1972)
Heath, J., Eranko, O., Eranko, L.: Effect of guanethidine on the ultrastructure of the small, granule-containing cells in cultures of rat sympathetic ganglia. Acta Pharmacol. Toxicol. (Kbh) 33, 209–218 (1973a)
Heath, J.W., Evans, B.K., Burnstock, G.: Axon retraction following guanethidine treatment. Z. Zellforsch. 146, 439–451 (1973b)
Heath, J.W., Hill, C.E., Burnstock, G.: Axon retraction following guanethidine treatment: Studies of sympathetic neurons in tissue culture. J. Neurocytol. 3, 263–276 (1974)
Heffernan, A., Carty, A., O’Malley, K., Bugler, J.: A within-patient comparison of debrisoquin and methyldopa in hypertension. Br. Med. J. 1, 75–78 (1971)
Heinonen, O.P., Shapiro, S., Tuominen, L., Turunen, M.I.: Reserpine use in relation to breast cancer. Lancet 2, 675–677 (1974)
Helling, M.: Experience with World Health Organization. In: Gouveia, W.A., Tognoni, G., Kleijn, E.V.D. (eds): Clinical pharmacy and clinical pharmacology. Amsterdam-New York- Oxford: North-Holland, (1976), pp. 141–151
Hensler, L.: Hypertonietherapie mit Serpasil, einem Alkaloid der Rauwolfia serpentina. Schweiz. Med. Wochenschr. 83, 1162–1166 (1953)
Hepp, R., Kreye, V.A.W.: Effect of long-term treatment with high doses of guanethidine on sperm transport and fertility in rats. Br. J. Pharmacol. 48, 30–35 (1973)
Hess, R.: Functional interpretation of drug-induced morphological changes. In: Advances in toxicological methodology. Proc. Eur. Soc. Study Drug Tox. Amsterdam-New York-London-Milan-Tokyo-Buenos Aires: Excerpta Medica, 130–140 (1965)
Hester, R.K., Carrier, O.: Reserpine supersensitity four hours after pretreatment of rabbits. Fed. Proc. 32, 405 (1973)
Hey, P., Willey, G.L.: Choline 2:6-xylyl ether bromide; an active quaternary local anaesthetic. Br. J. Pharmacol. 9, 471–475 (1954)
Hilden, T., Krogsgaard, A.R., Godtfredsen, E.: Behandling af hypertension med reserpin (Serpasil). Ugeskr. Laeger 117, 572–575 (1955)
Hilden, T., Nilsson, R.: Metyldopa i behandlingen af hypertension. T. Norsk. Laegeforen. 88, 1416–1420 (1968)
Hill, C.E., Mark, G.E., Eranko, O., Eranko, L., Burnstock, G.: Use of tissue culture to examine the actions of guanethidine and 6-hydroxydopamine. Eur. J. Pharmacol. 23, 162–174 (1973)
Hochuli, E., Weiche, V.: Zur Dauermedikation mit hypotensiven Substanzen in Graviditate. Geburtshilfe Frauenheilkd. 32, 32–39 (1972)
Hoffbrand, B.I., Fry, W., Bunton, G.L.: Cholestatic jaundice due to methyldopa. Br. Med. J. 3, 559 (1974)
Hoffeld, D.R., Webster, R.L., McNew, J.: Adverse effects on offspring of tranquilizing drugs during pregnancy. Nature (Lond.) 215, 182–183 (1967)
Hoffman, J.S., Domino, E.: Comparative effects of reserpine on the sleep cycle of man and cat. J. Pharmacol. Exp. Ther. 170, 190–198 (1969)
Holt, M.C.: Methoserpidine, A non-depressant isomer of reserpine. Br. Med. J. 2, 415–418 (1961)
Horwitz, D., Sjoerdsma, A.: Use of two enzyme inhibitors in hypertension therapy. Postgrad. Med. 34, 140–144 (1963)
Horwitz, D., Pettinger, W.A., Orvis, H., Thomas, R.E., Sjoerdsma, A.: Effects of methyldopa in fifty hypertensive patients. Clin. Pharmacol. Ther. 8, 224–234 (1967)
Hoyumpa, A.M., Connell, A.M.: Methyldopa hepatitis. Report of three cases. Am. J. Dig. Dis. 18, 213–222 (1973)
Hunter, E., Raik, E., Gordon, S.: Incidence of positive Coombs’ test, LE cells and antinuclear factor in patients on alpha-methyldopa (Aldomet) therapy. Med. J. Aust. 2, 810–812 (1971)
Hunter, K.R., Stern, G.M., Laurence, D.R.: Use of levodopa with other drugs. Lancet 2, 1283–1285 (1970)
Hurley, R.E., Page, I.H., Dustan, H.P.: Bretylium tosylate as an antihypertensive drug. J. Am. Med. Assoc. 172, 2081–2083 (1960)
Igloe, M.C.: Effects of methyldopa in hypertension. J. Am. Med. Assoc. 189, 188–190 (1964)
Innes, I.R., Krayer, O., Wand, D.R.: The action of rauwolfia alkaloids on the heart rate and on the functional refractory period of atrio-ventricular transmission in the heart-lung preparation of the dog. J. Pharmacol. Exp. Ther. 124, 324–332 (1958)
Irvine, R.O.H., O’Brien, K.P., North, J.D.K.: Alpha-methyldopa in treatment of hypertension. Lancet 1, 300–303 (1962)
Iversen, B.M., Johannesen, J.W., Nordahl, E., Ofstad, J., Thunold, S., Willassen, Y.: Retroperitoneal fibrosis during treatment with methyldopa. Lancet 2, 302–304 (1975)
Jackson, W.B.: Tolerance and side effects during long term treatment of hypertension with debrisoquine. Aust. N. Z. J. Med. 4, 357–365 (1972)
Jandhyala, B.S., Buckley, J.P.: Autonomic and cardiovascular effects of guanethidine in dogs. Circulation 50, Suppl. 3, 37 (1974)
Jandhyala, B.S., Cavero, I., Buckley, J.P.: Effects of chronic guanethidine administration on cardiovascular function of dogs. Res. Commun. Chem. Pathol. Pharmacol. 11, 523–532 (1975)
Jandhyala, B.S., Clarke, D.E., Buckley, J.P.: Effects of prolonged administration of certain antihypertensive agents. J. Pharm. Sci. 63, 1497–1513 (1974)
Janowsky, D.S., El-Yousef, M.K., Davis, J.M., Fann, W.E.: Antagonism of guanethidine by chlorpromazine. Am. J. Psychiatry 130, 808–812 (1973)
Janowsky, D.S., El-Yousef, M.K., Davis, J.M., Fann, W.E., Oates, J.A.: Guanethidine antagonism by antipsychotic drugs. J. Tenn. Med. Assoc. 65, 620–622 (1972)
Jensen-Holm, J.: Cholinesterases and protein changes in sympathetic ganglia after guanethidine. Acta Pharmacol. Toxicol. [Suppl. 4] (kbn) 25, 74 (1967)
Jensen-Holm, J.: The influence of guanethidine and ascorbic acid on the rat lymph nodes and thymus (weight, histology and cholinesterases). Acta Pharmacol. Toxicol. [Suppl. 1] (Kbh) 35, 33 (1974)
Jensen-Holm, J., Juul, P.: Changes of the rat superior cervical ganglion induced by guanethidine (histology and cholinesterase histochemistry). Br. J. Pharmacol. 34, 21 IP (1968)
Jensen-Holm, J., Juul, P.: The effects of guanethidine, pre- and postganglionic nerve division on the rat superior cervical ganglion: Cholinesterases and protein. Acta Pharmacol. Toxicol. (Kbh) 28, 270–282 (1970a)
Jensen-Holm, J., Juul, P.: The effects of guanethidine, pre- and postganglionic nerve division on the rat superior cervical ganglion: Cholinesterases and catecholamines (histochemistry), and histology. Acta Pharmacol. Toxicol. (Kbh). 28, 283–298 (1970b)
Jensen-Holm, J., Juul, P.: Ultrasructural changes in the rat superior cervical ganglion following prolonged guanethidine administration. Acta Pharmacol. Toxicol. (Kbh) 30, 308–320 (1971)
Jewett, R.E., Norton, S.: Effect of tranquilizing drugs on postnatal behavior. Exp. Neurol. 14, 33–43 (1966)
Jick, H.: Adverse drug effects in relation to renal function. Am. J. Med. 62, 514–517 (1977)
Johnson, E.M.: Destruction of the sympathetic nervous system of neonatal rats by vinblastine: Preventing by concomitant administration of nerve growth factor (NGF). Fed. Proc. 36, 956 (1977)
Johnson, E.M., Aloe, L.: Suppression of the in vitro and in vivo cytotoxic effects of guanethidine in sympathetic neurons by nerve growth factor. Brain Res. 81, 519–532 (1974)
Johnson, E.M., O’Brien, F.: Evaluation of the permanent sympathectomy produced by the administration of guanethidine to adult rats. J. Pharmacol. Exp. Ther. 196, 53 - 61 (1976)
Johnson, P., Kitchin, A.H., Lowther, C.P., Turner, R.W.D.: Treatment of hypertension with methyldopa. Br. Med. J. 1, 133–137 (1966)
Johnson, E.M., Cantor, E., Douglas, J.R.: Biochemical and functional evaluation of the sympathectomy produced by the administration of guanethidine to newborn rats. J. Pharmacol. Exp. Ther. 193, 503–512 (1975)
Johnson, E.M., O’Brien, F., Werbitt, R.: Modification and characterization of the permanent sympathectomy produced by the administration of guanethidine to newborn rats. Eur. J. Pharmacol. 37, 45–54 (1976)
Johnson, E.M., Macia, R.A., Yellin, T.O.: Marked difference in the susceptibility of several species to guanethidine-induced chemical sympathectomy. Life Sci. 20, 107–112 (1977)
Johnston, A.W., Prichard, B.N.C., Rosenheim, M.L.: The use of bethanidine in the treatment of hypertension. Lancet 2, 659–661 (1964)
Jones, D.L.B.H., Michael, A.M., Ommer, J.P.: Clinical trial of methoserpidine in general practice. Br. Med. J. 2, 1738–1741 (1961)
Jorstad, J.: Reserpin ved psykoser. Nord. Med. 55, 794–798 (1956)
Juul, P.: Effects of various antihypertensive guanidine derivatives on the adult rat superior cervical ganglion: Histology, ultrastructure, and cholinesterase histochemistry. Acta Pharmacol. Toxicol. (Kbh) 32, 500–512 (1973a)
Juul, P.: Accumulation of guanethidine by sympathetic ganglia of reserpinized rats. Acta Pharmacol. Toxicol. (Kbh) 33, 79–80 (1973b)
Juul, P.: Guanethidine and sympathetic ganglia. ( Thesis ). Copenhagen (1974)
Juul, P.: Cytotoxicity of a series of guanidine derivatives. In: Drug design and adverse reactions. Bundgaard, H., Juul, P., Kofod, H. (eds.). Copenhagen: Munksgaard, (1977), pp. 63–73
Juul, P., Mclsaac, R.L.: The effect of guanethidine on the noradrenaline content of the adult rat superior cervical ganglion. Acta Pharmacol. Toxicol. (Kbh) 32, 382–389 (1973)
Juul, P., Sand, O.: Determination of guanethidine in sympathetik ganglia. Acta Pharmacol. Toxicol. (Kbh) 32, 487–499 (1973)
Kaldor, A., Juvancz, P.: Effect of antihypertensive drugs on the “intrinsic” heart rate. Br. Med. J. 2, 486–487 (1969)
Kanematsu, S., Sawyer, C.H.: Effects of intrahypothalamic implants of reserpine on lactation and pituitary prolactin content in the rabbit. Proc. Soc. Exp. Biol. Med. 113, 967–969 (1963)
Katz, R.L., Weintraub, H.D., Papper, E.M.: Anesthesia, surgery and rauwolfia. Anesthesiology 25, 142–147 (1964)
Kedia, K., Markland, C.: The effect of pharmacological agents on ejaculation. J. Urol. 114, 569–573 (1975)
Kehl, R. Audibest, A., Gage, C., Amarger, J.: Action de la réserpine à différentes périodes de la gestation chez la lapine. C. R. Soc. Biol. (Paris) 150, 2196–2199 (1956)
Kellaway, G.S.M.: Adverse drug reactions during treatment of hypertension. Drugs 11, suppl. 1, 91–99 (1976)
Kellaway, G.S.M., McCrae, E.: Non-compliance and errors of drug administration in patients discharged from acute medical wards. N. Z. Med. J. 81, 508–512 (1975)
Kersting, F., Reid, J.L., Dollery, C.T.: Clinical and cardiovascular effects of alpha methyldopa in combination with decarboxylase inhibitors. Clin. Pharmacol. Ther. 21, 548–555 (1976)
Kert, M.J., Carleton, H.G., Nordyke, R.A., Roth, S.I., Smith, L.A., Westgart, J.P.: Clinical experiences with reserpine (Serpasil) in hypertension. Angiology 6, 138–143 (1955)
Khatri, I.M., Cohn, J.N.: Effect of sympathetic blockade on exercise-induced splanchnic vasoconstriction. Circulation 28., Suppl. 6, 114 (1968)
Kiessling, W., Huhnstock, K.: Aspermatismus nach peroralen Gaben von Guanethidin. Klin. Wochenschr. 41, 948–952 (1963)
Kincaid-Smith, P., Bullen, M., Mills, J.: Prolonged use of methyldopa in severe hypertension in pregnancy. Br. Med. J. 1, 274–276 (1966)
Kisin, I., Yuzhakov, S.: Effects of reserpine, guanethidine and methyldopa on cardiac output and its distribution. Eur. J. Pharmacol. 35, 253–260 (1976)
Kitchin, A.H., Turner, R.W.D.: Studies on debrisoquine sulphate. Br. Med. J. 2, 728–731 (1966)
Klein, H.O., Kaminsky, N.: Methyldopa fever. Recurrence of symptoms with resumption of therapy. N. Y. State J. Med. 73, 448–451 (1973)
Koch-Weser, J.: Drug interactions in cardiovascular therapy. Am. Heart. J. 90, 93–116 (1975)
Kopia, G.A., Condouris, G.A.: Guanethidine-induced cardiac arrhythmias in cats anesthetized with halothane. Fed. Proc. 36, 1013 (1977)
Kopin, I.J.: False adrenergic transmitters. Annu. Rev. Pharmacol. Toxicol. 8, 377–394 (1968)
Kostrzewa, R.M., Jacobowitz, D.M.: Pharmacological actions of 6-hydroxydopamine. Pharmacol. Rev. 26, 199–288 (1974)
Krogsgaard, A.R.: Reserpine and gastric secretion in man. Acta Med. Scand. 158, 1–11 (1957a)
Krogsgaard, A.R.: The effect of reserpine on the electrolyte and fluid balance in man. Acta Med. Scand. 159, 127–132 (1957b)
Krogsgaard, A.R.: Side-effects of reserpine in the treatment of essential hypertension. Acta Med. Scand. 162, 465–474 (1958)
Krogsgaard, A.R.: On reserpine with particular reference to its use in hypertension. (Thesis). Copenhagen, Munksgaard (1961)
Kuntzman, R., Jacobson, M.M.: Monoamine oxidase inhibition by a series of compounds structurally related to bretylium and guanethidine. J. Pharmacol. Exp. Ther. 141, 166–172 (1963)
Kwan, K.C., Foltz, E.L., Breault, G.O., Baer, J.E., Totaro, J.A.: Pharmacokinetics of methyldopa in man. J. Pharmacol. Exp. Ther. 198, 264–277 (1976)
Landesman, R., McLarn, W.D., Oilskin, R.N., Mendelsohn, B.: Reserpine in toxemia of pregnancy. Obstet. Gynecol. 9, 377–383 (1957)
Laragh, J.H. (ed.): Hypertension manual. New York, Dun-Donnelley (1973)
Laska, E.M., Siegel, C., Meisner, M., Fischer, S., Wanderling, J.: Matched pairs study of reserpine use and breast cancer. Lancet 2, 296–300 (1975)
Lauler, D.P., Vagnucci, A.I., Hickler, R.B., Thorn, G.W.: Clinical features of sodium retention induced by antihypertensive therapy. Circulation 28, 754–755 (1963)
Laurence, D.R., Nagle, R.E.: The interaction of bretylium with pressor agents. Lancet 1, 593–594 (1961)
Laurence, D.R., Rosenheim, M.L.: Clinical effects of drugs which prevent the release of adrenergic transmitter. In: Vane, J.R. (ed.): Adrenergic mechanisms. CIBA symposium. London: Churchill, 201 - 208 (1960)
Lauwers, P., Verstraete, M., Joossens, J.V.: Methyldopa in the treatment of hypertension. Br. Med. J. 1, 295–300 (1963)
Lee, P.A., Kelly, M.R., Wallin, J.D.: Increased prolactin levels in patients during reserpine treatment of hypertensive patients. J. Am. Med. Assoc. 235, 2316–2317 (1976)
Leishman, A.W.D., Matthews, H.L., Smith, A.J.: Guanethidine. Hypotensive drug with prolonged action. Lancet 2, 1044–1048 (1959)
Leishman, A.W.D., Matthews, H.L., Smith, A.J.: Further experience with guanethidine. Lancet 2, 4–7 (1961)
Leishman, A.W.D., Matthews, H.L., Smith, A.J.: Antagonism of guanethidine by imipramine. Lancet 1, 112 (1963)
Lemieux, G., Davignon, A., Genest, J.: Depressive states during Rauwolfia therapy for arterial hypertension. Can. Med. Assoc. J. 4, 522–526 (1956)
Lemmer, B., Sailer, R., Grobecker, H.: Increased cardiac turnover of noradrenaline after chronic administration of guanethidine in the rat. Experientia (Basel) 30, 379–381 (1974)
Leonard, J. W., Gifford, R.W., Humphrey, D.C.: Febrile reactions to L-alpha-methyl-dopa. Cleve. Clin. Q. 29, 144–147 (1962)
Leonard, J.W., Gifford, R.W., Humphrey, D.C.: Treatment of hypertension with methyldopa alone or combined with diuretics and/or guanethidine. Am. Heart J. 69, 610–618 (1965)
Leth, A.: Body fluid compartments in essential hypertension. ( Thesis ). Copenhagen (1976)
Leth, A., Ibsen, H.: Changes in plasma and extracellular fluid volume during long-term treatment with alpha-methyldopa in 11 thiazide-treated patients with essential hypertension. Acta Med. Scand. 198, 45–48 (1975)
Leth, A., Ibsen, H.: Changes in the ratio of plasma to interstitial fluid volume during long-term antihypertensive therapy. J. Lab. Clin. Med. 87, 781–791 (1976)
Levi, J., Robson, M., Rosenfeld, J.: The treatment of hypertension. Comparative trial of bethanidine (Esbatal) and bethanidine with reserpine. Clinical Trials Journal 17, 263–270 (1970)
Levi-Montalcini, R., Angeletti, P.U.: Immunosympathectomy. Pharmacol. Rev. 18, 619–628 (1966)
Levi-Montalcini, R., Aloe, L., Johnson, E.M.: Interaction between the nerve growth factor (NGF) and adrenergic blocking agents in sympathetic neurons. Front. Catecholamine Res. 267–276 (1973)
Levine, R.J., Strauch, B.S.: Hypertensive response to methyldopa. N. Engl. J. Med. 275, 946–948 (1966)
Lewis, P.D., Patel, A.J., Béndek, G., Balâzs, T.: Do drugs acting on the nervous system affect cell proliferation in the developing brain. Lancet 1, 399 (1977)
Lieberman, A.R.: The axon reaction: A review of the principal features of perikaryal responses to axon injury. In: International review of neurobiology. Pfeffer, C.C., Smythies, J.R. (eds.). London: Academic Press, (1971), Vol. 14, pp. 49–124
Lifrak, I.L., Strebel, R., Settles, H.: The effect of reserpine on the cardiac muscle of pregnant and fetal guinea pigs. Fed. Proc. 35, 611 (1976)
Lilienfeld, A.M., Chang, L., Thomas, D.B., Levin, M.L.: Rauwolfia derivatives and breast cancer. John Hopkins Med. J. 139, 41–50 (1976)
Lobuglio, A.F., Jandl, J.H.: The nature of the alpha-methyldopa red-cell antibody. N. Engl. J. Med. 276, 658–665 (1967)
Locket, S.: Oral preparations of Rauwolfia serpentina in treatment of essential hypertension. Br. Med. J. 1, 809–813 (1955)
Lorez, H.-P., Kettler, R.: Absence of degeneration of adrenergic neurons after prolonged treatment of newborn rats with debrisoquin. Acta Pharmacol. Toxicol. (Kbh) 36, 132–144 (1975)
Loumanmäki, K., Heikkila, J., Härtel, G.: Bretylium tosylate. Adverse effects in acute myocardial infarction. Arch. Intern. Med. 135, 515–518 (1975)
Lown, B., Ehrlich, L., Lipschulz, B., Blake, J.: Effect of digitalis in patients receiving reserpine. Circulation 24, 1185–1191 (1961)
Lowther, C.P., Turner, R.W.D.: Guanethidine in the treatment of hypertension. Br. Med. J. 2, 776–781 (1963)
Luizzi, A., Foppen, F.H., Angeletti, P.U.: Adrenaline, noradrenaline and dopamine levels in brain and heart after administration of 6-hydroxydopamine and guanethidine to newborn mice. Biochem. Pharmacol. 23, 1041–1044 (1974)
Luke, R.G., Kennedy, A.C.: Methyldopa in treatment of hypertension due to chronic renal disease. Br. Med. J. 1, 27–30 (1964)
Lüllmann, H., Lüllmann-Rauch, R., Wassermann, O.: Arzneimittelinduzierte Phospholipid-speicherkrankheit. Dtsch. Med. Wochenschr. 98, 1616–1625 (1973)
Lund-Johansen, P.: Hemodynamic changes in long-term alpha-methyldopa therapy of essential hypertension. Acta Med. Scand. 192, 221–226 (1972)
Lund-Johansen, P., Hemodynamic changes in long-term therapy of essential hypertension: A comparative study of diuretics, a-methyldopa and Clonidine. Clin. Sci. Mol. Med. 45, Suppl. 1, 199S–203S (1973)
Mack, T.M., Henderson, B.E., Gerkins, V.R., Arthur, M., Baptista, J., Pike, M.: Reserpine and breast cancer in a retirement community. N. Engl. J. Med. 292, 1366–1371 (1975)
Mackay, I.R., Cowling, D.C., Hurley, T.H.: Drug-induced autoimmune disease: Haemolytic anaemia and lupus cells after treatment with methyldopa. Med. J. Aust. 2, 1047–1050 (1968)
Macmahon, F.G., Ryan, J.R., Jain, A.K., Vargas, R., Vanov, S.K.: Guanabenz in essential hy¬pertension. Clin. Pharmacol. Ther. 21, 272–277 (1977)
Maddrey, W.C., Boitnott, J.K.: Severe hepatitis from methyldopa. Gastroenterology 68, 351–360 (1975)
Malmfors, T., Thoenen, H. (eds.): 6-hydroxydopamine and catecholamine neurons. Amsterdam-London: North-Holland, (1971)
Malmquist, J., Oates, J.A.: Effects of adrenergic neuron-blocking guanidine derivatives on mitochondrial metabolism. Biochem. Pharmacol. 17, 1845–1854 (1968)
Manohitharajah, S.M., Jenkins, W.J., Roberts, P.D., Clarke, R.C.: Methyldopa and associated thrombocytopenia. Br. Med. J. 1, 494 (1971)
Marcus, G.J., Stevenson, M., Brown, T.: Alpha-methyldopa-induced immune thrombocytopenia. Am. J. Clin. Path. 64, 113–115 (1975)
Märdh, P.A., Beifrage, I., Naversten, E.: Sialadenitis following treatment with α-methyldopa. Acta Med. Scand. 195, 333–335 (1974)
Marino, A.: Ricerche sperimentali su elcuni effetti psichici e cardiaci dell’ l-fenil-2-pirrolodino-pentano e della stricnina. Rass. med. Sper. 9, 1–33 (1962)
Marley, E., Pare, C.M.B.: Cardiac failure with reserpine. Br. Med. J. 1, 267–269 (1956)
Marshall, A.J., Roberts, C.J.C., Barritt, D.W.: Raynaud’s phenomenon as side effect of beta-blockers in hypertension. Br. Med. J. 1, 1498–1499 (1976)
Mathisen, HJ.: Clinical studies with methyldopa (Aldomet) in patients with hypertension during two years. Acta Med. Scand. 174, 183–192 (1963)
Matthews, M.R., Raisman, G.: A light and electron microscopic study of the cellular response to axonal injury in the superior cervical ganglion of the rat. Proc. R. Soc. Lond. [Biol.] 181, 43–79 (1972)
Matts, S.G.F.: A comparative trial of Clonidine (Catapres) and guanethidine (Ismelin) in the treatment of hypertension. J. Int. Med. Res. 3, 21–25 (1975)
Maxwell, R.A., Mull, R.P., Plummer, A.J.: [2-octahydro-(l-azocinyl)-ethyl]-guanidine sulfate (CIBA 5864-SU), a new synthetic antihypertensive agents. Experientia (Basel) 15, 267 (1959)
Maxwell, R.A., Plummer, A.J., Schneider, F., Povalski, H., Daniel, A.I.: Pharmacology of [2- (octahydro-l-azocinyl)-ethyl] guanidine sulfate (SU-5864). J. Pharmacol. Exp. Ther. 128, 22–29 (1960)
McAllister, R.G.: Guanethidine in antihypertensive therapy: Experience with an oral loading regimen. J. Clin. Pharmacol. 15, 771–778 (1975)
McGeer, P.L., Boulding, J.E., Gibson, W.C., Foulkes, R.G.: Drug-induced extrapyramidal reactions. J. Am. Med. Assoc. 177, 665–670 (1961)
McKinney, W.T., Kane, F.J., Depression with the use of alpa-methyldopa. Am. J. Psychiat. 124, 80–81 (1967)
McKinney, W.T., Eising, R.G., Moran, E.C., Suomi, S.J.: Effects of reserpine on the social behavior of rhesus monkeys. Dis. Nerv. Syst. 32, 735–741 (1971)
McLaren, E.H.: Severe hypertension produced by interaction of phenylpropanolamine with methyldopa and Oxprenolol. Br. Med. J. 2, 283–284 (1976)
McMartin, C., Rondel, R.K., Vinter, J., Allan, B.R., Humberstone, P.M., Leishman, A.W.D., Sandler, G., Thirkette, J.L.: The fate of guanethidine in two hypertensive patients. Clin. Pharmacol. Ther. 11, 423–431 (1970)
McQueen, E.G.: New Zealand Committee on Adverse Drug Reactions: Ninth annual report 1974. N. Z. Med. J. 80, 305–311 (1974)
Melick, R., McGregor, M.: Reserpine and extracellular-fluid volume. N. Engl. J. Med. 256, 1000–1002 (1957)
Merceron, R., Weiss, Y., Safar, M., Milliez, P.: Comparaison des effets hémodynamiques de la Clonidine, de l’alpha méthyl dopa, de la guanéthidine, et de la réserpine: Etude préliminaire. Thérapie 28, 93–101 (1973)
Merck Institute Information. In: Barnes, C.D., Eltherington, L.G. Drug dosage in laboratory animals. Berkeley-Los Angeles-London: University California Press, (1973), p. 162
Meyer, J.F., McAllister, C.K., Goldberg, L.I.: Insidious and prolonged antagonism of guanethidine by amitriptyline. J. Am. Med. Assoc. 213, 1487–1488 (1970)
Miller, A.C.: Methyldopa-induced granulomatous hepatitis. J. Am. Med. Assoc. 235, 2001–2002 (1976)
Miller, R.D., Way, W.L., Eger, E.I.: The effects of alpha-methyldopa, guanethidine and iproniazid on minimum alveolar anesthetic requirement (MAC). Anestesiology 29, 1153–1158 (1968)
Misage, J.R., McDonald, R.H.: Antagonism of hypotensive action of bethanidine by “common cold” remedy. Br. Med. J. 4, 347 (1970)
Mitchell, J.R., Oates, J.A.: Guanethidine and related agents. I. Mechanism of the selective blockade of adrenergic neurons and its antagonism by drugs. J. Pharmacol. Exp. Ther. 172, 100–107 (1970)
Mitchell, J.R., Arias, L., Oates, J.A.: Antagonism of the antihypertensive action of guanethidine sulfate by desipramine hydrochloride. J. Am. Med. Assoc. 202, 973–975 (1967)
Mitchell, J.R., Cavanaugh, J.H., Arias, L., Oates, J.A.: Guanethidine and related agents. III. Antagonism of drugs which inhibit the norepinephrine pump in man. J. Clin. Invest. 49, 1596–1604 (1970)
Mohammed, S., Hanenson, I.B., Magenheim, H.G., Gaffney, T.E.: The effects of alpha-methyldopa on renal function in hypertensive patients. Am. Heart J. 76, 21–27 (1968)
Mohan, M.C., Johnson, E.S.: Hypothermia during treatment with alpha methyl dopa (a case report). J. Assoc. Physicians India 23, 221–225 (1975)
Montuschi, E., Lovel, T.W.I.: Guanoxan in hypertension. Lancet 2, 1339–1340 (1964)
Moore, J.I., Moran, N.C.: Cardiac contractile force responses to ephedrine and other sympathomimetic amines in dogs after pretreatment with reserpine. J. Phamacol. Exp. Ther. 136, 89–96 (1962)
Morin, Y., Turmel, L., Fortier, J.: Methyldopa: Clinical studies in arterial hypertension. Am. J. Med. Sci. 248, 633–639 (1964)
Morrison, A.B., Webster, R.A.: Drug-induced experimental parkinsonism. Neuropharmacology 12, 715–724 (1973a)
Morrison, A.B., Webster, R.A.: Reserpine rigidity and adrenergic neurones. Neuropharmacology 12, 725–733 (1973b)
Moyer, J.H.: Cardiovascular and renal hemodynamic responses to reserpine and clinical results of using this agent for the treatment in hypertension. Ann. N. Y. Acad. Sci. 59, 82–94 (1954)
Moyer, J.H., Hughes, W., Huggins, R.: The cardiovascular and renal hemodynamic response to the administration of reserpine (Serpasil). Am. J. Med. Sci. 227, 640–648 (1954)
Mroczek, W.J., Leibel, B.A., Finnerty, F.A.: Comparison of Clonidine and methyldopa in hypertensive patients receiving a diuretic. Am. J. Cardiol. 29, 712–717 (1972)
Muelheims, G.H., Brown, G.O., Effect of guanethidine therapy on total blood volume in patients with essential hypertension. Proc. Soc. Exp. Biol. Med. 109, 613–615 (1962)
Muelheims, G.H., Entrup, R.W., Paiewonsky, D., Mierzwiak, D.S.: Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine. Clin. Pharmacol. Ther. 6, 757–762 (1965)
Mull, R.P., Maxwell, R.A.: Guanethidine and related adrenergic neuronal blocking agents. In: Antihypertensive agents. Schiitter, E. (ed.). New York-London: Academic Press, (1967), pp. 115–149
Mull, R.P., Maxwell, R.A., Plummer, A.J.: Antihypertensive activity of hexahydro-l-azepine-propionamidoxime. Nature (Lond.) 180, 1200–1201 (1957)
Müller, J.C., Pryor, W.W., Gibbons, J.E., Organ, E.S.: Depression and anxiety occurring during rauwolfia therapy. J. Am. Med. Assoc. 159, 836–839 (1955)
Müller, J.M., Schiitter, E., Bein, H.J.: Reserpin, der sedative Wirkstoff aus Rauwolfia serpen¬tina Benth. Experientia (Basel) 8, 338 (1952)
Mullick, F.G., McAllister, H.A.: Myocarditis associated with methyldopa therapy. J. Am. Med. Assoc. 237, 1699–1701 (1977)
Murr, G.: Einfluß des Reserpins auf die Nasenschleimhaut. Laryngol. Rhinol. Otol. (Stuttg.) 55, 178–185 (1976)
Muscholl, E.: Adrenergic false transmitters. In: Catecholamins. Blaschko, H., Muscholl, E. (eds.): Handbook of experimental pharmacology, Vol. 33, Berlin-Heidelberg-New York: Springer Verlag, (1972), pp. 618–660
Muscholl, E., Maitre, L.: Release by sympathetic stimulation of α-methyl-noradrenaline stored in the heart after administration of α-methyldopa. Experientia (Basel) 19, 658–659 (1963)
Nash, D.T.: Clinical trial with guanabenz, a new antihypertensive agent. J. Clin. Pharmacol. 13, 416–421 (1973)
Nayler, W.G.: A direct effect of reserpine on ventricular contractility. J. Pharmacol. Exp. Ther. 139, 222–229 (1963)
Neely, C.L., Kraus, A.P.: Mechanisms of drug-induced hemolytic anemia. Adv. Intern. Med. 18, 59–76 (1972)
Neuhaus, A.W.: Nebenwirkungen psychotroper Substanzen an den Epithelien der Milchdrüse, des Uterus unter der Nebenniere bei der Ratte. Acta Anat. (Basel) 90, 101–116 (1974)
Newball, H.H., Byar, D.P.: Does reserpine increase prolactin and exacerbate cancer of prostate. Urology 11, 525–529 (1973)
Newman, R.J.: Sexual dysfunction due to methyldopa. Br. Med. J. 4, 106 (1974)
Nielsen, G.D.: Guanethidine induced acute hypersensitivity to noradrenaline in anaesthetized rats. Acta Pharmacol. Toxicol. (Kbh) 40, 273–279 (1977a)
Nielsen, G.D.: Guanethidine induced sympathectomy in the adult rat. I. Functional effects following subacute administration. Acta Pharmacol. Toxicol. (Kbh) 41, 203–208 (1977b)
Nielsen, G.D.; Guanethidine induced sympathectomy in the adult rat. II. Functional effects following chronic administration. Acta Pharmacol. Toxicol. (Kbh) 41, 209–217 (1977c)
Nies, A.S.: Adverse reactions and interactions limiting the use of antihypertensive drugs. Am. J. Med. 58, 495–503 (1975)
Nowack, P.: The effect of guanethidine on renal, cerebral and cardiac hemodynamics. In: Hypertension - recent advances. Brest, A.N., Moyer, J.H. (eds.): Philadelphia: Lea & Fibiger, (1961) pp. 444–448
Nydegger, U., Miescher, P.A.: Immunological mechanisms in drug-induced blood dyscrasias. J. Clin. Path. 28, Suppl. 9, 46–49 (1975)
Oates, J.: Distribution of guanidinium antihypertensives - mechanism of their selective action. Drug Intelligence and Clinical Pharmacy 4, 349 (1970)
Oates, J. A.: Drug interactions in man. A critical appraisal of their relative role in interindividual variations in drug response. In: Pharmacology and the future of man. Problems of therapy. Okita, T., Acheson, G.H. (eds.). Basel: Karger, Vol. 3, 1973 pp. 191–199
Oates, J.A., Gillespie, L., Udenfriend, S., Sjoerdsma, A.: Decarboxylase inhibition and blood pressure reduction by a-methyl-3,4-dihydroxy-DL-phenylalanine. Science 131, 1890–1891 (1960)
Oates, J.A., Seligman, A.W., Clark, M.A., Rousseau, P., Lee, R.E.: The relative efficacy of guanethidine, methyldopa and pargyline as antihypertensive agents. N. Engl. J. Med. 273, 729–734 (1965)
Ober, K.F., Wang, R.I.H.: Drug interactions with guanethidine. Clin. Pharmacol. Ther. 14, 190–195 (1973)
O’Donnell, S.R., Saar, N.: The effects of 6-hydroxydopamine and guanethidine on peripheral adrenergic nerves in the guinea pig. Eur. J. Pharmacol. 28, 251–256 (1974)
O’Fallon, W.M., Labarthe, D.R., Kurland, L.T.: Rauwolfla derivatives and breast cancer. Lancet 2, 292–296 (1975)
Onesti, G., Brest, A.N., Nowack, P., Kasparian, H., Moyer, J.H.: Pharmacodynamic effects of alpha-methyl dopa in hypertensive subjects. Am. Heart. J. 67, 32–38 (1964)
Onesti, G., Laschiazza, D., Brest, A.N., Moyer, J.H.: Cardiac and renal hemodynamic effects of debrisoquin sulfate in hypertensive subjects. Clin. Pharmacol. Ther. 7, 17–20 (1966)
O’Regan, J.B.: Adverse interaction of lithium carbonate and methyldopa. Can. Med. Assoc. J. 115, 385–386 (1976)
Page,I.H., Dustan, H.P.: A bew, potent antihypertensive drug. Preliminary study of [2-(octahy- dro-l-azocinyl)-ethyl]-guanidine sulfate (guanethidine). J. Am. Med. Assoc. 170, 1265–1271 (1959)
Page, I.H., Dustan, H.P.: Persistence of normal blood pressure after discontinuing treatment in hypertensive patients. Circulation 25, 433–436 (1962)
Page, I.H., Hurely, R.E., Dustan, H.P.: The prolonged treatment of hypertension with guanethidine. J. Am. Med. Assoc. 175, 543–549 (1961)
Parks, V.J., Sandison, A.G., Skinner, S.L., Whelan, R.F.: The mechanism of the vasodilator action of reserpine in man. Clin. Sci. Mol. Med. 20, 289–295 (1961)
Pascual, A.V., Julius, S.: Short term effectiveness and hemodynamic actions of guanadrel, a new sympatholytic drug. Curr. Ther. Res. 14, 333–342 (1972)
Paykel, E.S.: Hallucinosis on combined methyldopa and pargyline. Br. Med. J. 1, 803 (1966)
Pearson, M., Meerkin, M., Baird, C.: Aldomet interference with the Babson method of SGOT analysis. Med. J. Aust. 2, 84–85 (1972)
Peart, W.S., MacMahon, M.T.: Clinical trial of 2-guanidinomethyl (1,4) benzodioxan (compound 1003). Br. Med. J. 1, 398–402 (1964)
Peaston, M.J.T.: Parkinsonism associated with alpha-methyldopa therapy. Br. Med. J. 2, 168 (1964)
Perera, G.A.: Edema and congestive failure related to administration of rauwolfla serpentina. J. Am. Med. Assoc. 159, 439 (1955)
Perry, H.M., Chaplin, H., Carmody, S., Haynes, C., Frei, C.: Immunologic findings in patients receiving methyldopa: A prospective study. J. Lab. Clin. Med. 78, 905–917 (1971)
Pettinger, W.A., Horwitz, D., Sjoerdsma, A.: Lactation due to methyldopa. Br. Med. J. 1, 146 (1963a)
Pettinger, W.A., Horwitz, D., Spector, S., Sjoerdsma, A.: Enhancement by methyldopa of tyramine sensitivity in man. Nature (Lond.) 200, 1107–1108 (1963b)
Pettinger, W.A., Korn, A., Spiegel, H., Solomon, H.M., Pocelinko, R., Abrams, W.B.: Debrisoquin, a selective inhibitor of intraneuronal monoamine oxidase in man. Clin. Phamacol. Ther. 10, 667–674 (1969)
Petz, L.D., Fudenberg, H.H.: Immunologic mechanisms in drug-induced cytopenias, Progr. Hematol. 9, 185–206 (1975)
Pfeifer, H.J., Greenblatt, D.J., Koch-Weser, J.: Clinical toxicity of reserpine in hospitalized patients: A report from the Boston Collaborative Drug Surveillance Program. Am. J. Med. Sci. 271, 269–276 (1976)
Pirsig, W., Proescher, K., Donath, K.: Zur Ultrastruktur geschädigter Nerven in der Parotis bei Guanacline-therapierten Hypertonikern: morphologische Substrate zum Parotisschmerz. Arch. klin. exp. Ohren Nasen Kehlkopfheilk. 205, 103–109 (1973)
Platt, R., Sears, H.T.N.: Reserpine in severe hypertension. Lancet 1, 401–403 (1956)
Plummer, A.J., Earl, A., Schneider, A.E., Trapold, J., Barrett, W.: Pharmacology of rauwolfia alkaloids, including reserpine. Ann. N. Y. Acad. Sci. 59, 8–21 (1955)
Plummer, A.J., Barrett, W.E., Maxwell, R.A., Finocchio, D., Lucas, R.A., Earl, A.E.: Hypotensive properties of syrosingopine, SU-3118, an ester of methyl reserpate. Arch. Int. Pharmacodyn. Ther. 119, 245–257 (1959)
Pozos, R.S., Holbrook, J.R.: Tremoregenesis: Effects of reserpine on the substantia nigra. Exp. Neurol. 32, 317–330 (1971)
Prichard, B.N.C.: Aspects of the evaluation of antihypertensive drugs. Arch. int. Pharmacodyn. Ther. 192, suppl., 193–208 (1971)
Prichard, B.N.C., Johnston, A.W., Hill, I.D., Rosenheim, M.L.: Bethanidine, guanethidine, and methyldopa in treatment of hypertension: A within-patient comparison. Br. Med. J. 1, 135–144 (1968)
Pugsley, E.B.: Adverse reactions to methyldopa. Can. Med. Assoc. J. 106, 1064 (1972)
Quetsch, R.M., Achor, R.W.P., Litin, E.M., Faucett, R.L.: Depressive reactions in hypertensive patients. Circulation 19, 366–375 (1959)
Rahn, K.H., Rupp, W.: Plasma levels and urinary excretion of guanethidine in hypertensive patients. Acta Pharmacol. Toxicol (Kbh) 29, suppl. 4, 46 (1971)
Ramsay, L.E.: Liver dysfunction in hypertension. Lancet 2, 111–114 (1977)
Ravina, J.H.: Les thérapeutiques dangereuses chez la femme enciente. Presse Med. 72, 3057 (1964)
Rechardt, L., Hervonen, H.: Ultrastructural changes in the neural lobe of the rat pituitary induced by reserpine treatment. Experientia (Basel) 31, 1205–1207 (1975)
Redman, C.W.G., Beilin, L.J., Bonnar, J., Ounsted, M.K.: Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet 2, 753–756 (1976)
Rehman, O.U., Keith, T.A., Gall, E.A.: Methyldopa-induced submassive hepatic necrosis, J. Am. Med. Assoc. 224, 1390–1392 (1973)
Reilly, J.F., Ahlstrom, A.P., Watts, J.S., Cassidy, P.S., Lusky, L.M.: Influence of age, sex, and cold exposure on susceptibility to reserpine-induced gastric lesions. Toxicol. Appl. Pharmacol. 15, 97–105 (1969)
Reusch, C.S.: The cardiorenal hemodynamic effects of antihypertensive therapy with reserpine. Am. Heart. J. 64, 643–649 (1962)
Richardson, D.W., Wyso, E.M.: Human pharmacology of guanethidine. Ann. N. Y. Acad. Sci. 88, 944–955 (1960)
Richardson, D.W., Wyso, E.M., Magee, J.H., Cavell, G.C.: Circulatory effects of guanethidine. Circulation 22, 184–190 (1960)
Richter, K.: Einfluß des Reserpins auf das exokrine Pankreas der Ratte. Zentralbl. Allg. Pathol. 119, 329 (1975)
Roberts, J., Modell, W.: Pharmacological evidence for the importance of catecholamines in cardiac rhythmicity. Circ. Res. 9, 171–176 (1961)
Roberts, J., Ito, R., Reilly, J., Cairoli, V.J.: Influence of reserpine and βTM10 on digitalis-induced ventricular arrhytmia. Circ. Res. 13, 149–158 (1963)
Robinson, B.: Breast changes in the male and female with chlorpromazine or reserpine therapy. Med. J. Aust. 2, 239–241 (1957)
Rodman, J.S., Deutsch, D.J., Gertman, S.I.: Methyldopa hepatitis. A report of six cases and review of the literature. Am. J. Med. 60, 941–948 (1976)
Roland, E.Q., Safar, M.E., Lelquen, C.E., Aboras, Y.A., Weiss, Y.A., Milliez, P.M.: Effect of certain antiadrenergic agents an systolic time intervals in essential hypertension. Eur. J. Clin. Pharmacol. 11, 423–427 (1977)
Romeo, S.G., Whalen, R.E., Tindall, J.P.: Intra-arterial administration of reserpine. Arch. Intern. Med. 125, 825–829 (1970)
Ronnov-Jessen, V.: Blood-volume during treatment of hypertension. Acta. Med. Scand. 174, 307–310 (1963)
Ronnov-Jessen, V., Hansen, J.: Blood volume and exchangeable sodium during treatment of hypertension with guanethidine and hydrochlorothiazide. Acta Med. Scand. 186, 255–263 (1969)
Rosenbloom, S.E., Shapera, R.P., Goldbloom, R.S., Sheps, M.C., Shapiro, A.P.: Technic of controlled drug assay. III. Comparison of guanethidine, mecamylamine and a placebo in the hypertensive patient. N. Engl. J. Med. 268, 797–803 (1963)
Rosendorff, C., Marsden, C.D., Cranston, W.I.: Clinical evaluation of debrisoquin in the treatment of hypertension. Arch. J. Intern. Med. 122, 487–490 (1968)
Ruedy, J., Davies, R.O.: A comparative clinical trial fo guanoxan and guanethidine in essential hypertension. Clin. Pharmacol. Ther. 8, 38–47 (1967)
Russo, C., Mendlowitz, M.: The effect of guancydine on blood pressure, vascular reactivity, and norepinephrine uptake in essential hypertension. Clin. Pharmacol. Ther. 13, 875–878 (1972)
Safar, M., Simon, A., Maiz, H.B., Weiss, Y., Milliez, P.: Hypertensions artérielles sévères traitées médicalement. Nouv. Presse Med. 4, 1403–1406 (1975)
Samee, H.J., Klug, P., Zalandek, G., Sterz, H.: Orthostatische Hypotonie nach Cyclazenin-Medikation. Wien Med. Wochenschr. 120, 56–60 (1970)
Sandler, G., Leishmann, A.W.D., Humberstone, P.M.: Guanethidine-resistent hypertension. Circulation 38, 542–551 (1968)
Sannerstedt, B., Bojs, G., Varnauskas, E., Werkö, L.: Alpha-methyldopa in arterial hypertension. Clinical, renal, and hemodynamic studies. Acta Med. Scand. 174, 53–67 (1963)
Sannerstedt, R., Conway, J.: Hemodynamic and vascular responses to antihypertensive treatment with adrenergic blocking agents: A review. Am. Heart J. 79, 122–127 (1970)
Sannerstedt, R., Varnauskas, E., Werkö, L.: Hemodynamic effects of methyldopa (Aldomet) at rest and during exercise in patients with arterial hypertension. Acta Med. Scand. 171, 75–82 (1962)
Sataline, L., Lowell, D.: Delayed hepatotoxicity from methyldopa. Conn. Med. 39, 775–776 (1975a)
Sataline, L., Lowell, D.: Methyldopa toxicity. Gastroenterology 70, 148–149 (1957b)
Schiitter, E., Druey, J., Marxer, A.: Antihypertensive agents. In: Progress in drug research. Jucker, E. (ed.): Basel-Stuttgart: Birkhäuser Verlag, Vol. 4, (1962) pp. 297–351
Schreader, C.J., Etzl, M.M.: Premature ventricular contractions due to Rauwolfia therapy. J. Am. Med. Assoc. 162, 1256 (1956)
Schroeder, H.A., Perry, H.M.: Psychosis apparently produced by reserpine. J. Am. Med. Assoc. 159, 839–841 (1955)
Schweitzer, I.L., Peters, R.L.: Acute submassive hepatic necrosis due to methyldopa. Gastroenterology 66, 1203–1211 (1974)
Scott, J.N., McDevitt, D.G.: Rebound hypertension after acute methyldopa withdrawal. Br. Med. J. 2, 367 (1976)
Scott, M.G., Zaimis, E.: Histological changes in the heart following treatment with reserpine. J. Physiol. (Lond.) 162, 8P (1962)
Seedat, Y.K., Vawda, E.I.: The Coombs test and methyldopa. Lancet 1, 427 (1968)
Seedat, Y.K., Vawda, E.I.: Direct Coombs test and methyldopa. Lancet 1, 97 (1972)
Shand, D.G., Nies, A.S., McAllister, R.G., Oates, J.A.: An improved method for treating severe hypertension with guanethidine. Clin. Res. 20, 413 (1972)
Shand, D.G., Nies, A.S., McAllister, R.G., Oates, J.A.: A loading-maintenance regimen for more rapid initiation of the effect of guanethidine. Clin. Pharmacol. Ther. 18, 139–144 (1975)
Shapiro, A.P., Teng, H.C.: Technic of controlled drug assay illustrated by a comparative study of Rauwolfia serpentina, phenobarbital and placebo in the hypertensive patient. N. Engl. J. Med. 256, 970–975 (1957)
Sharon, E., Paolino, J.S., Kaplan, D.: Hematemesis after reserpine for Raynaud’s phenomenon. Ann. Intern. Med. 77, 479 (1972)
Sheps, S.G., Schirger, A., Osmundson, P.J., Fairbairn, J.F.: Methyldopa for treatment of hypertension. J. Am. Med. Assoc. 184, 616–621 (1963)
Sherman, J.D., Love, D.E., Harrington, J.F.: Anemia, positive lupus and rheumatoid factors with methyldopa. Arch. Intern. Med. 120, 321–326 (1967)
Shore, P.A., Brodie, B.B.: LSD-like effects elicited by reserpine in rabbits pretreated with ipronizid. Proc. Soc. Exp. Biol. Med. 94, 433–435 (1957)
Silva, J.A.F. de, Capaceia, J.P. de O., Cohen, I.: Assessment of a new antihypertensive agent, 2,6-dichlorbenzylidene amino guanidine acetate (guanabenz). A double-blind, crossover trial against placebo. Pharmatherapeutica 1, 1–7 (1976)
Simpson, F.O.: Deserpidine: A controlled trial of a Rauwolfia alkaloid. Med. J. Aust. 2, 821–823 (1961)
Simpson, F.O. (ed.): Symposium on hypertension. Drugs 11, Suppl. 1, 1–204 (1976)
Singh, H.P., Hebert, M.A., Gault, M.H.: Effect of some drugs on clinical laboratory values as determined by the Technicon SMA 12/60. Clin. Chem. 18, 137–144 (1972)
Skinner, C., Coull, D.C., Johnston, A.W.: Antagonism of the hypotensive action of bethanidine and debrisoquine by tricyclic antidepressants. Lancet 2, 564–566 (1969)
Smirk, H.: Hypotensive action of methyldopa. Br. Med. J. 1, 146–151 (1963a)
Smirk, H.: The hypotensive action of B. W. 467C60. Lancet 1, 743–746 (1963b)
Smirk, F.H., McQueen, E.G.: Comparison of rescinnamine and reserpine as hypotensive agents. Lancet 2, 115–116 (1955)
Smith, A.J.: Clinical features of fluid retention complicating treatment with guanethidine. Circulation 31, 485–489 (1965a)
Smith, A.J.: Fluid retention produced by guanethidine. Circulation 31, 490–496 (1965b)
Smith, C.: Effects of reserpine and alpha-methyldopa upon adrenergic nerve function in the guinea pig heart. In: The nervous system in arterial hypertension. Julius, S., Esler, M.D. (eds.): Springfield-Illinois: Charles C. Thomas, (1976) pp. 442–453
Smith, W.M., Bachman, B., Galante, J.G., Hanowell, E.G., Johnson, W.P., Koch, C.E., Korfmacher, S.D., Thurm, R.H., Broomer, L.: Co-operative clinical trial of alpha-methyldopa. III. Double-blind control comparison of alpha-methyldopa and chlorothiazide and chlorothiazide and Rauwolfia. Ann. Intern. Med. 65, 657–671 (1966)
Smulyan, H., Markason, C.R., Keighley, M., Cuddy, R.P., Eich, R.H., Lyons, R.H.: Effects of reserpine on the circulation and on the circulatory responses to tilting and norepinephrine. Am. J. Cardiol. 11, 743–756 (1963)
Snaith, R.P., McCourbrie, M.: Antihypertensive drugs and depression. Psychol. Med. 4, 393–398 (1974)
Sneddon, J.M., Turner, P.: Ephedrine mydriasis in hypertension and the response to treatment. Clin. Pharmacol. Ther. 10, 64–71 (1969a)
Sneddon, J.M., Turner, P.: The interaction of local guanethidine and sympathomimetic amines in the human eye. Arch. Ophthal. 81, 622–627 (1969b)
Sobel, D.E.: Fetal damage due to ECT, insulin coma, chlorpromazine, or reserpine. Arch. gen. Psychiatry. 2, 606–611 (1960)
Soloff, L.A.: Clinical pharmacology and therapeutic use of bretylium tosylate. In: Hypertension - recent advances. Brest, A.N., Moyer, J.H. (eds.): Philadelphia: Lea & Fibiger, (1961) pp. 432–436
Soloff, L.A., Reidenberg, M., Winters, W.L., Bello, C.T.: Clinical experiences with bretyliumtosylate. Ann. N. Y. Acad. Sci. 88, 1003–1010 (1960)
Somlyo, A.P., Waye, J.D.: Abnormal lactation. Report of a case induced by reserpine and a brief review of the subject. J. Mt. Sinai Hosp. 27, 5–9 (1960)
Spach, M.O., Bloch, R., Velly, J., Imbs, J.L., Bousquet, P., Schwartz, J.: Guérison apparante de l’hypertension artérielle. Nouv. Presse Med. 3, 241–243 (1974)
Spann, J.F., Sonnenblick, E.H., Cooper, T., Chidsey, C.A. William, V.L., Braunwald, E.: Cardiac norepinephrine stores and the contractile state of heart muscle. Circ. Res. 19, 317–325 (1966)
Starr, K.J., Petrie, J.C.: Drug interactions in patients on long-term oral anticoagulant and antihypertensive adrenergic neuron-blocking drugs. Br. Med. J. 4, 133–135 (1972)
Steiner, J., Cassar, J., Mashiter, K., Dawes, I., Fraser, T.R., Breckenridge, A.: Effects of methyldopa on prolactin and growth hormone. Br. Med. J. 1, 1186–1188 (1976)
Steiner, G., Schönbaum, E. (eds): Immunosympathectomy. Amsterdam-London-New York: Elsevier (1972)
Stern, W.C., Morgane, P.J.: Effects of reserpine on sleep and brain biogenic amine levels in the cat. Psychopharmacology 28, 275–286 (1973)
Stevens, F.R.T.: A danger of sympathomimetic drugs. Med. J. Aust. 2, 576 (1966)
Stitzel, R.E.: The biological fate of reserpine. Pharmacol. Rev. 28, 179–205 (1976)
Stocks, A.E., Robertson, A.: The long-term therapy of severe hypertension with guanethidine. Am. Heart J. 73, 569–570 (1967)
Stone, C.A., Ross, C.A., Wenger, H.C., Ludden, C.T., Blessing, J.A., Totaro, J.A., Porter, C.C.: Effect of α-methyl-3,4-dihydrocyphenylalanine (methyldopa), reserpine and related agents on some vascular responses in the dog. J. Pharmacol. Exp. Ther. 136, 80–88 (1962)
Stone, C.A., Porter, C.C., Stavorski, J.M., Ludden, C.T., Totaro, J.A.: Antagonism of certain effects of catecholamine-depleting agents by antidepressants and related drugs. J. Pharmacol. Exp. Ther. 144, 196–204 (1964)
Stuart, K.L., Maclver, C., Nicholson, J.A.: Outpatient treatment trial of mild and severe hypertension. Br. Med. J. 2, 21–24 (1972)
Sun, S.-C., Sohal, R.S., Colcolough, H.L., Burch, G.E.: Histochemical and electron microscopic studies of the effects of reserpine on the heart muscle of mice. J. Pharmacol. Exp. Ther. 161, 210–221 (1968)
Swedish Adverse Reactions Committee: Biverkninger av metyldopa under 10 âr. Communication no. 26, may (1977)
Sweet, R.D., Lee, J.E., McDowell, F.H.: Methyldopa as an adjuvant to levodopa treatment of Parkinson’s disease. Clin. Pharmacol. Ther. 13, 23–27 (1972)
Talbot, F.J.: Clinical evaluation of the antihypertensive effects of debrisoquin, a new postganglionic vasodepressor agent. Med. Ann. D.C. 34, 580–583 (1965)
Talbot, S., Smith, A.J.: Factors predisposing to postural hypotensive symptoms in the treatment of high blood pressure. Br. Heart J. 37, 1059–1063 (1975)
Talbot, S., O’Malley, B.C., Bing, R.F.: Debrisoquine, guanethidine, and bethanidine in hypertension. Br. Med. J. 2, 278 (1975)
Tallgren, L.G., Servo, C.: Hyperpyrexia in association with L-alpha methyl dopa. A report of two cases. Acta Med. Scand. 186, 223–226 (1969)
Tarpley, E.L.: Controlled trial of guanethidine and methyldopa in moderate hypertension. Curr. Ther. Res. 16, 1187–1196 (1974)
Taylor, R.E., Fregly, M.J.: Effect of reserpine on body temperature regulation of the rat. J. Pharmacol. Exp. Ther. 138, 200–207 (1962)
Ten Pas, A., de Leeuw, N.K.M., Stacey, C.H.: Methyldopa-induced thrombocytopenia. Can. Med. Assoc. J. 95, 322 (1966)
Tester-Dalderup, C.B.M.: Hypotensive drugs. In: Meyler’s side effects of drugs. Dukes, M.N.G. (ed.): Vol. 8. Amsterdam-Oxford: Excerpta Medica, (1976) pp. 461–482
Tester-Dalderup, C.B.M.: Hypotensive drugs. In: Side effects of drugs, annual 1. Dukes, M.N.G. (ed.) Amsterdam-Oxford: Excerpa Medica, (1977) pp. 164–179
Thoenen, H.: Surgical, immunological and chemical sympathectomy. In: Catecholamines. Blaschko, H., Muscholl, E. (eds.): Handbook of experimental pharmacology, Vol. 33. Berlin-Heidelberg-New York: Springer Verlag. (1972a) pp. 813–844
Thoenen, H.: Chemical sympathectomy: A new tool in the investigation of the physiology and pharmacology of peripheral and central adrenergic neurons. In: Perspectives in neuropharmacology. Snyder, S.H. (ed.) New York-London-Toronto: Oxford University Press, (1972b) pp. 301–338
Thoenen, H., Tranzer, J.P.: The pharmacology of 6-hydroxydopamine. Annu. Rev. Pharmacol. Toxicol. 13, 169–180 (1973)
Thomas, E., Bhula, S., Rosenthal, W.S.: Methyldopa-induced liver injury. Rapid progression to fatal postnecrotic cirrhosis. Arch. Pathol. Lab. Med. 100, 132–135 (1976)
Thornton, W.E.: Dementia induced by methyldopa with haloperidol. N. Engl. J. Med. 294, 1222 (1976)
Tissot, R.: The effect of certain drugs on the sleep cycle in man. In: Progress in brain research. Sleep mechanisms. Akert, K., Bally, C., Schadé, J.P. (eds.) Vol. 18, Amsterdam: Elsevier (1965) pp. 175–177
Toghill, P.J., Smith, P.G., Benton, P., Brown, R.C., Matthews, H.L.: Methyldopa liver damage. Br. Med. J. 3, 545–548 (1974)
Trendelenburg, U.: Factors influencing the concentration of catecholamines at the receptors. In: Catecholamines. Blashcko, H., Muscholl, E. (eds.) Handbook of experimental pharmacology, Vol. 33. Berlin-Heidelberg-New York: Springer Verlag, (1972) pp. 726–761
Trendelenburg, U., Weiner, N.: Sensitivity of the nictitating membrane after various procedures. J. Pharmacol. Exp. Ther. 136, 152–161 (1962)
Tripod, J., Bein, H.J., Meier, R.: Characterization of central effects of serpasil (reserpin, a new alkaloid of rauwolfia serpentina B) and of their antagonistic reaction. Arch. Int. Pharmacodyn. Ther. 96, 406–425 (1954)
Tuchmann-Duplessis, H., Mercier-Parot, L.: Repercussions de la réserpine sur la gestation chez la ratte. C. R. Acad. Sci. (Paris) 243, 410–412 (1956)
Tuchmann-Duplessis, H., Mercier-Parot, L.: Malformation foetales chez le rat traité par de fortes doses de deserpidine. C. R. Soc. Biol. (Paris) 155, 2291 (1961)
Turkington, R.W.: Prolactin secretion in patients treated with various drugs. Arch. Intern. Med. 130, 349–354 (1972)
Tysell, J.E., Knauer, C.M.: Hepatitis induced by methyldopa (Aldomet). Am. J. Dig. Dis. 16, 849–855 (1971)
Vakil, R.J.: A clinical trial of Rauwolfia serpentina in essential hypertension. Br. Heart J. 2, 350–355 (1949)
Vedin, J.A., Wilhelmsson, C.-E., Werkô, L.: Comparative study of alprenolol and methyldopa in previously untreated essential hypertension. Br. Heart J. 35, 1285–1292 (1973)
Vejlsgaard, V.: Betanidin (Esbatal, Regulin) ved behandling af hypertension. Ugeskr. Laeger 130, 134–136 (1968)
Vejlsgaard, V., Christensen, M., Clausen, E.: Double-blind trial of four hypotensive drugs (methyldopa and three sympatholytic agents). Br. Med. J. 2, 598–600 (1967)
Veterans Administration Cooperative Study Group on Antihypertensive Agents: A double- blind control study of antihypertensive effectiveness of reserpine and hydralazine, and three ganglionic blocking agents. Arch. Intern. Med. 106, 81–96 (1960)
Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. J. Am. Med. Assoc. 213, 1143–1152 (1970)
Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension. III. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation 45, 991–1004 (1972)
Villareal, H., Exaire, J.E., Rubio, V., Dâvila, H.: Effect of guanethidine and bretylium tosylate on systemic and renal hemodynamics in essential hypertension. Am. J. Cardiol. 14, 633 - 640 (1964)
Vyas, G.N., Sassetti, R.J., Petz, L.D., Fudenberg, H.H.: Experimental study of aldomet-induced positive antiglobulin reaction. Br. J. Haematol. 16, 137–143 (1969)
Wallace, D.C.: Treatment of hypertension. Hypotensive drugs and mental changes. Lancet 2, 116–117 (1955)
Walter, I.E., Nies, A.S.: Safety of single large doses of guanethidine. Clin. Pharmacol. Ther. 21, 706–708 (1977)
Walter, I.E., Khandelwal, J., Falkner, F., Nies, A.S.: The relationship of plasma guanthidine levels to adrenergic blockade. Clin. Pharmacol. Ther. 18, 571–580 (1975)
Weil, M.H., Barbour, B.H., Chesne, R.B.: Alpha-methyl dopa for the treatment of hypertension. Circulation 28, 165–174 (1963)
Weil, J.V., Chidsey, C.A.: Plasma volume expansion resulting from interference with adrebergic function in normal men. Circulation 37, 54–61 (1968)
Weiss, Y., Merceron, R., Safar, M., Milliez, P.: Action anti-hypertensive de quatre drogues inhibant le système nerveux sympathique. Coeur Med. Interne 12, 425–429 (1973)
Wells, J.D., Kurtay, M., Lochner, J.C., George, W.L.: Granulomatous skin lesions and alphamethyldopa. Ann. Intern. Med. 81, 701–702 (1974)
Welsch, C.W., Meites, J.: Effects of reserpine on development of 7,12-dimethylbenzantracene induced mammary tumors in female rats. Experientia (Basel) 26, 1133–1134 (1970)
Werboff, J., Dembicki, E.L.: Toxic effects of tranquilizers administered to gravid rats. J. Neuropsychiatry 4, 87–91 (1962)
Werboff, J., Havlena, J.: Postnatal behavioral effects of tranquilizers administered to the gravid rat. Exp. Neurol. 6, 263–269 (1962)
Werboff, J., Kesner, R.: Learning deficits of offspring after administration of tranquilizing drugs to the mothers. Nature (Lond.) 197, 106–107 (1963)
Werboff, J., Gottlieb, J.S., Havlena, J., Word, T.J.: Behavioral effects of prenatal drug administration in the white rat. Pediatrics 27, 318–324 (1961)
West, G.B.: Drugs and rat pregnancy. J. Pharm. Pharmacol. 14, 828–830 (1962)
West, W.O.: Perforation and hemorrhage from duodenal ulcer during administration of rauwolfia serpentina: Report of five cases. Ann. Intern. Med. 48, 1033–1039 (1959)
West, W.L., Baird, G.M., Steward, J.D., Pradhan, S.N.: Some studies on the anti-tumor effect of reserpine in mice. J. Pharmacol. Exp. Ther. 131, 171–178 (1961)
Westfall, D.P.: The effects of denervation, cocaine, 6-hydroxydopamine and reserpine on the characteristics of drug-induced contractions of the depolarized smooth muscle of the rat and guinea-pig vas deferens. J. Pharmacol. Exp. Ther. 201, 267–275 (1977)
White, A.G.: Methyldopa and amitriptyline, Lancet 2, 441 (1965)
Wilcken, D.E.L., Brender, D., Shorey, D., MacDonald, G.J.: Reserpine: Effect on structure of heart muscle. Science 157, 1332–1334 (1967a)
Wilcken, D.E.L., MacDonald, G.J., Brender, D.: Mitochondrial changes following pharmacological depletion of myocardial catecholamines. Aust. Ann. Med. 16, 364–365 (1967b)
Wilkins, R.W., Judson, W.E.: The use of rauwolfia serpentina in hypertensive patients. N. Engl. J. Med. 248, 48–53 (1953)
Williams, R.L., Maines, J.E., Pearson, J.E.: Direct und systemic effects of guanethidine on renal function. J. Pharmacol. Exp. Ther. 177, 69–77 (1971)
Williams, R.B., Sherter, C.: Cardiac complications of tricyclic antidepressant therapy. Ann.Intern. Med. 74, 395–398 (1971)
Wilson, R., Long, C.: Action of bretylium antagonised by amphetamine. Lancet 2, 262 (1960)
Wilson, W.R., Okun, R., Tetreault, L., Fallis, N.: Methyldopa and hydrochlorothiazide in primary hypertension. J. Am. Med. Assoc. 185, 819–825 (1963)
Wilson, B.N., Wimberley, N.A.: Production of premature ventricular contractions by Rauwolfia. J. Am. Med. Assoc. 159, 1363–1364 (1955)
Withrington, P., Zaimis, E.: The reserpine-treated cat. Br. J. Pharmacol. 17, 380–391 (1961)
Withrington, P., Zaimis, E.: Cardiovascular effects produced in cats by the chronic administration of small doses of reserpine. Carciovasc. Res. 1, 52–62 (1967)
Wollam, G.L., Gifford, R.W., Tarazi, R.C.: Antihypertensive drugs: Clinical pharmacology and therapeutic use. Drugs 14, 420–460 (1977)
Wollweber, H., Wilms, H., Hiltmann, R., Stoepel, K., Kroneberg, G.: Guanidinoalkyl-aza- cycloalkane: Chemische Struktur und antihypertensive Wirkung. Arzneim. Forsch. 21, 2089–2100 (1971)
Wongs, H.Y.C., Nightingale, T.E., David, S.N., Orimlikwe, S.O., Reinshagen, J.A.: Effects of exercise, guanethidine or its combination on hemodynamic changes in atherosclerotic cockerels. Physiologist 18, 455 (1975)
Woods, J.W., Blythe, W.B., Huffines, W.D.: Management of malignant hypertension complicated by renal insufficiency. N. Engl. J. Med. 291, 10–14 (1974)
Woosley, R.L., Nies, A.S.: Guanethidine. N. Engl. J. Med. 295, 1053–1057 (1976)
Woosley, R.L., Walter, I., Oates, J.A., Nies, A.S.: Antagonism of the antihypertensive and sympathoglegic effects of guanethidine by ephedrine in man. Clin. Res. 24, 259A (1976)
Worlledge, S.M., Carstairs, K.C., Dacie, J.V.: Autoimmune haemolytic anaemia associated with α-methyldopa therapy. Lancet 2, 135–139 (1966)
Yamadori, A., Albert, M.L.: Involuntary movement disorder caused by methyldopa. N. Engl. J. Med. 286, 610 (1972)
Yen,H.C.Y., Katz, M.H., Krop, S.: Effects of various drugs on 3,4-dihydroxyphenylalanine (DL-DOPA)-induced excitation (aggressive behavior) in mice. Toxicol. Appl. Pharmacol. 17, 597–604 (1970)
Zaimis, E.: Reserpine-induced circulatory failure. Nature (Lond.) 192, 521–523 (1961)
Zaimis, E.: Functional, biochemical, and morphological changes produced by hypotensive drugs. In: Antihypertensive therapy. Gross, F. (ed.) Berlin-Heidelberg-New York: Springer Verlag, (1966) pp. 59–70
Zaimis, E. (ed): Nerve growth factor and its antiserum. Athlone Press of the University of London (1972)
Zarday, Z., Rosenthal, W.S., Wolff, F.W.: Severe liver toxicity after methyldopa. N. Y. State J. Med. 2, 1897–1899 (1967)
Zimmermann, A.M., Harris, L.S.: Microcirculation: Effects of guanethidine and reserpine. J. Pharmacol. Exp. Ther. 142, 76–82 (1963)
Zimmerman, H.J.: Liver disease caused by medical agents. Med. Clin. North. Am. 59, 897–907 (1975)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Juul, P. (1981). Toxic Effects of Adrenergic Nerve-End Inhibitors, Neural-Transmitter Depleting Agents and False Transmitters. In: Szekeres, L. (eds) Adrenergic Activators and Inhibitors. Handbook of Experimental Pharmacology, vol 54 / 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-67584-3_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-67584-3_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-67586-7
Online ISBN: 978-3-642-67584-3
eBook Packages: Springer Book Archive